Supplemental Report

Strategic Analysis of the Small Molecule cGAS Inhibitor Landscape: Clinical, Scientific, and Commercial Dynamics

Executive Summary

The cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) pathway represents a critical node in innate immunity, sensing aberrant cytosolic DNA and triggering inflammatory responses, primarily through Type I interferons (IFN-I). While essential for host defense, chronic or inappropriate activation of this pathway is increasingly implicated in the pathogenesis of numerous autoimmune and inflammatory diseases, including systemic lupus erythematosus (SLE) and rare interferonopathies like Aicardi-Goutières Syndrome (AGS). Consequently, inhibiting cGAS, the pathway's primary DNA sensor, has emerged as a highly attractive therapeutic strategy, offering the potential for targeted intervention upstream of broad inflammatory cascades.

This report provides a comprehensive strategic analysis of the small molecule cGAS inhibitor landscape, extending beyond patent filings to encompass clinical development, recent scientific advancements, business development activities, inferred target product profiles, and regulatory considerations. The field has recently achieved significant milestones, with two orally available small molecule cGAS inhibitors, ImmuneSensor Therapeutics' IMSB-301 and Ventus Therapeutics' VENT-03, successfully completing initial Phase 1 clinical studies in healthy volunteers. Both candidates demonstrated acceptable safety and pharmacokinetic profiles supporting advancement into patient trials. ImmuneSensor is initiating Phase 1b/2 studies targeting AGS, SLE, and cutaneous lupus erythematosus (CLE), leveraging Orphan Drug and Rare Pediatric Disease Designations granted by the FDA for AGS. Ventus plans to initiate a Phase 2 trial for VENT-03 in SLE in 2025, positioning it as the first cGAS inhibitor to reach this stage for a major autoimmune indication.

The scientific landscape continues to evolve rapidly. Beyond the likely catalytic site inhibition mechanism of the lead clinical candidates, research published since 2023 highlights novel inhibitory strategies, including targeting the cGAS-DNA binding interface, allosteric modulation, covalent inhibition, and modulation of liquid-liquid phase separation. New chemical scaffolds, such as pyrimidine amides and natural product-derived flavonoids, are demonstrating preclinical promise. Concurrently, a deeper understanding of cGAS biology is emerging, including its complex regulation via post-translational modifications and its non-canonical roles within the nucleus related to DNA repair and genome stability.

Commercially, the cGAS inhibitor space is attracting significant investment and strategic interest. Ventus Therapeutics has secured substantial venture funding ($>300M total), driven partly by its ReSOLVE® structure-based design platform. Major pharmaceutical companies are actively engaged, evidenced by Novartis' $835M potential acquisition of IFM Due for its STING *antagonist* program, providing a key competitive or complementary approach to cGAS inhibition. The recent option deal between Veralox Therapeutics and Nudge Therapeutics for preclinical cGAS inhibitors signifies growing interest even in earlier-stage assets.

Inferred Target Product Profiles (TPPs) for both IMSB-301 and VENT-03 converge on oral, likely once-daily administration for chronic autoimmune diseases, primarily SLE. Differentiation will hinge on clinical efficacy, safety, and potentially targeting specific patient populations, possibly guided by IFN biomarkers. ImmuneSensor's initial focus on the genetically defined rare disease AGS, supported by regulatory designations, represents a distinct strategic approach compared to Ventus' direct move towards the larger SLE market.

The strategic outlook for cGAS inhibitors is promising but carries inherent risks. Key opportunities lie in demonstrating clinical proof-of-concept in interferonopathies like AGS and SLE, potentially offering a targeted oral alternative to existing therapies. Expansion into broader inflammatory or neurodegenerative conditions remains a long-term possibility. However, challenges include translating biomarker modulation into clear clinical benefit, ensuring long-term safety, navigating a competitive landscape that includes STING antagonists, and potentially identifying appropriate patient subsets. Successful clinical execution, leveraging biomarkers, and monitoring the dynamic scientific and commercial environment will be critical for companies aiming to capitalize on the therapeutic potential of cGAS inhibition.

1. Introduction: The cGAS Pathway and Therapeutic Rationale for Inhibition

1.1. Overview of the cGAS-STING Pathway

The innate immune system serves as the first line of defense against pathogens and cellular stress. A central component of this system is the cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) pathway, responsible for detecting the presence of DNA in the cytoplasm, a cellular compartment where DNA should not normally reside in healthy cells.[1] cGAS (encoded by *CGAS*/*MB21D1*) acts as the primary sensor, recognizing double-stranded DNA (dsDNA) irrespective of its sequence.[4] This aberrant DNA can originate from invading pathogens like viruses and bacteria, or from the host itself due to cellular damage, stress, or dysfunction leading to leakage of nuclear or mitochondrial DNA (mtDNA) into the cytosol.[1]

Upon binding dsDNA, cGAS undergoes conformational changes and oligomerization, activating its enzymatic function.[7] As a nucleotidyltransferase, activated cGAS utilizes cytosolic adenosine triphosphate (ATP) and guanosine triphosphate (GTP) to synthesize a unique cyclic dinucleotide, 2'3'-cyclic GMP-AMP (cGAMP).[2] This 2'3'-cGAMP molecule functions as a crucial second messenger.[2]

cGAMP diffuses through the cytoplasm and binds with high affinity to the STING protein (also known as TMEM173, MITA, ERIS, MPYS), an adaptor protein anchored in the membrane of the endoplasmic reticulum (ER).[2] Ligand binding induces conformational changes and oligomerization of STING, triggering its translocation from the ER, typically to the Golgi apparatus.[7] This activated STING complex then serves as a scaffold to recruit and activate downstream kinases, primarily TANK-binding kinase 1 (TBK1) and potentially IκB kinase ε (IKKε).[4]

TBK1 subsequently phosphorylates the transcription factor Interferon Regulatory Factor 3 (IRF3). Phosphorylated IRF3 dimerizes, translocates to the nucleus, and drives the expression of Type I Interferons (IFN-I), such as IFN-α and IFN-β.[4] STING activation can also lead to the activation of the Nuclear Factor-κB (NF-κB) pathway, resulting in the production of various pro-inflammatory cytokines like TNF, IL-6, and IL-1β.[7] The release of IFN-I and inflammatory cytokines orchestrates a broad innate immune response and helps prime adaptive immunity.[1]

Beyond this canonical signaling cascade, cGAS and STING are involved in other cellular processes. cGAS has been implicated in cellular senescence, recognition of micronuclei (often formed due to genomic instability in cancer cells), and potentially inhibiting DNA repair pathways.[1] STING activation is also linked to autophagy induction.[7] Furthermore, cGAS function is regulated by various mechanisms, including subcellular localization (with distinct roles proposed for nuclear cGAS [7]) and post-translational modifications (PTMs) such as phosphorylation, acetylation, and ubiquitination, which fine-tune its activity and stability.[7]

1.2. Aberrant cGAS Activation in Disease

While the cGAS-STING pathway is vital for protecting against infection, its inappropriate or chronic activation by self-derived DNA can drive pathological inflammation and contribute to the development of autoimmune and autoinflammatory diseases.[1] This occurs when mechanisms for clearing cytosolic self-DNA fail, or when cellular stress leads to excessive leakage of nuclear or mitochondrial DNA.[1] The resulting persistent production of IFN-I is a hallmark of several conditions collectively termed "Type I interferonopathies".[1]

Specific examples where aberrant cGAS-STING activation is implicated include:

- **Systemic Lupus Erythematosus (SLE):** A complex, chronic autoimmune disease affecting multiple organs. Evidence suggests increased levels of circulating dsDNA and elevated cGAMP/cGAS levels in some SLE patients.[9] This self-DNA, potentially contained within apoptotic vesicles, may continuously stimulate the cGAS-STING pathway, contributing to the characteristic IFN-I signature and inflammation seen in SLE.[4]
- **Aicardi-Goutières Syndrome (AGS):** A rare, severe genetic autoinflammatory disorder often presenting in infancy. AGS is frequently caused by mutations in genes encoding nucleases responsible for degrading endogenous nucleic acids, such as *TREX1*.[5] The resulting accumulation of cytosolic self-DNA leads to constitutive cGAS-STING activation and massive overproduction of IFN-I, causing neuroinflammation and systemic symptoms.[5]
- **STING-Associated Vasculopathy with onset in Infancy (SAVI):** Another rare interferonopathy caused by gain-of-function mutations in the *TMEM173* gene encoding STING itself.[9] These mutations lead to ligand-independent, constitutive STING activation and subsequent IFN-I overproduction, resulting in severe systemic inflammation, particularly affecting the vasculature and lungs.[9]
- **Rheumatoid Arthritis (RA):** In this chronic autoimmune joint disease, increased levels of cytoplasmic dsDNA have been observed in fibroblast-like synoviocytes, and cGAS expression correlates with synovitis severity. Knockdown studies suggest the pathway contributes to the inflammatory milieu in RA joints.[9]
- **Other Conditions:** The cGAS-STING pathway has also been linked to the pathogenesis of Sjogren's syndrome, dermatomyositis, systemic sclerosis, various neurodegenerative diseases (including Parkinson's disease, Alzheimer's disease, Huntington's disease, Amyotrophic Lateral Sclerosis (ALS), and Frontotemporal Dementia (FTD)), metabolic disorders (like non-alcoholic steatohepatitis (NASH)), cardiovascular diseases (myocardial infarction, heart failure), age-related macular degeneration (AMD), chronic obstructive pulmonary disease (COPD), and processes related to cellular senescence and aging.[1]

1.3. Rationale for Small Molecule cGAS Inhibition

Given the central role of cGAS in initiating pathological inflammation in these diverse conditions, inhibiting its activity presents a compelling therapeutic strategy.[1] Targeting the most upstream sensor specific to aberrant DNA offers potential advantages over inhibiting downstream components like STING, TBK1, or IFN receptors. Specifically, cGAS inhibition may provide greater pathway specificity, potentially avoiding the blockade of other signaling pathways that converge on STING or TBK1, and might carry a lower risk of broad immunosuppression compared to targeting downstream effectors like IFN-I.[13]

The therapeutic rationale is strongly supported by genetic evidence. For example, knockout of cGAS in mouse models of AGS (Trex1-deficient mice) prevents the lethal autoimmune

phenotype typically observed, demonstrating that cGAS is a critical driver of the disease.[1] Similarly, cGAS or STING knockout rescues the embryonic lethality caused by DNase II deficiency.[4] These findings solidify cGAS as a high-value drug target for diseases driven by inappropriate IFN-I production and autoimmunity.[5]

The development of specific, potent, and cell-permeable small molecule inhibitors of cGAS is therefore a major goal for treating these conditions. Such inhibitors could reduce the pathogenic production of IFN-I and other inflammatory cytokines, thereby ameliorating disease symptoms.[13] However, achieving this goal has historically been challenging. Early efforts identified compounds with biochemical activity, such as PF-06928215, but these often lacked significant activity in cellular assays, potentially due to poor cell permeability or competition with high intracellular concentrations of ATP and GTP at the enzyme's active site.[5] The recent advancement of candidates like IMSB-301 and VENT-03 into clinical trials signifies that these hurdles are being overcome, ushering in a new phase for cGAS inhibitor therapeutics.

The pursuit of cGAS inhibitors reflects a broader evolution in autoimmune disease treatment. Rather than relying solely on systemic immunosuppressants, which often carry significant side effects like increased infection risk [11], the field is moving towards more targeted modulation of specific pathways identified as key drivers of pathology in certain patient subsets. The strong preclinical validation for cGAS, particularly the rescue of severe autoimmune phenotypes in genetic knockout models [1], provides a compelling argument for this targeted approach. The initial clinical focus on defined interferonopathies like AGS and subsets of SLE [80] further exemplifies this strategy. Success in these populations could pave the way for biomarker-driven approaches, potentially using IFN gene signatures [12] to select patients most likely to benefit in more complex diseases like SLE, thereby advancing personalized medicine in autoimmunity.

2. Clinical Development Landscape of Small Molecule cGAS Inhibitors

The therapeutic potential of cGAS inhibition has spurred significant drug discovery efforts, culminating recently in the entry of the first small molecule cGAS inhibitors into human clinical trials. Two companies, ImmuneSensor Therapeutics and Ventus Therapeutics, are leading this charge with their respective oral candidates, IMSB-301 and VENT-03.

2.1. Lead Clinical Candidate: IMSB-301 (ImmuneSensor Therapeutics)

ImmuneSensor Therapeutics, founded based on the seminal discoveries of Dr. Zhijian "James" Chen regarding the cGAS-STING pathway [84], is developing IMSB-301 as a potential best-in-class, orally available small molecule cGAS inhibitor.[80]

- **Clinical Status and Design:** IMSB-301 entered a Phase 1 clinical trial in healthy volunteers

in Australia, with dosing initiated in the third or fourth quarter of 2024.[104] The trial, registered under ISRCTN90049550 [106], is a randomized, double-blind, placebo-controlled study. It is designed to evaluate single ascending doses (SAD) across up to five dose levels and multiple ascending doses (MAD) across up to three levels. Each cohort enrolls eight subjects (6 receiving IMSB-301, 2 receiving placebo). In the MAD portion, subjects receive twice-daily (BID) oral administration for seven days, followed by a single morning dose on Day 8.[81] The target enrollment is 64 participants.[108]

- **Endpoints:** The primary objective is to assess the safety and tolerability of IMSB-301, monitored through physical examinations, vital signs, laboratory tests (hematology, coagulation, biochemistry, urinalysis), electrocardiograms (ECGs), and adverse event (AE) reporting.[81] Secondary endpoints include characterizing the plasma pharmacokinetic (PK) profile of IMSB-301 after single and multiple doses, including a preliminary assessment of food effect (high-fat meal).[81] Crucially, target engagement (cGAS inhibition) will be evaluated in the MAD cohorts using an *ex vivo* whole blood DNA stimulation assay.[81]
- **Molecule Profile & Preclinical Data:** IMSB-301 is specifically designed to inhibit the enzymatic activity of cGAS, thereby preventing the synthesis of cGAMP and halting downstream pathological inflammation.[81] Preclinical studies reportedly demonstrated potent and specific inhibition of cGAS, leading to significant suppression of cytokine production and, notably, rescue from premature death and disease phenotype in a mouse model of AGS.[81]
- **Target Indications:** ImmuneSensor's initial clinical development strategy focuses on cGAS-driven Type I interferonopathies. AGS is the primary target indication for subsequent Phase 1b/2 patient studies, given its clear genetic link to the pathway.[104] Defined patient populations with CLE and SLE are planned secondary targets.[104] The company also notes potential future applicability in broader conditions like diabetic kidney disease, age-related macular degeneration (AMD), and other autoimmune disorders.[81]
- **Reported Results & Timelines:** As of October 2024, the first SAD cohort had completed dosing, with observed exposure levels and PK reported to be consistent with predictions from nonclinical studies.[83] ImmuneSensor anticipates reporting safety, PK, and target engagement data from the full Phase 1 trial by the end of 2024.[104] Positive results are expected to enable a rapid transition to Phase 1b/2 studies in patients with AGS, CLE, and SLE.[104]

2.2. Lead Clinical Candidate: VENT-03 (Ventus Therapeutics)

Ventus Therapeutics, founded in 2019 [110], has rapidly advanced VENT-03, positioning it as the first small molecule cGAS inhibitor to successfully complete a Phase 1 clinical trial.[88]

- **Clinical Status and Design:** VENT-03 completed a Phase 1 first-in-human trial in 72 healthy

adult volunteers between January 2024 and October 2024.[87] The trial evaluated PK, target engagement, safety, and tolerability across a wide range of single and multiple ascending doses.[88] Ventus is now planning to initiate Phase 2 development.[87]

- **Endpoints (Phase 1):** The Phase 1 study assessed PK, target engagement, safety, and tolerability.[88]
- **Molecule Profile & Preclinical Data:** VENT-03 is described as a first-in-class, potent, selective, oral cGAS inhibitor.[87] Its discovery was enabled by Ventus' proprietary ReSOLVE® platform, which integrates structural biology and advanced computational tools to understand protein dynamics and design optimized molecules.[70] Preclinical studies demonstrated excellent PK properties and robust pharmacodynamic activity, including efficacy in the Trex1-/- mouse model (relevant for SLE/AGS), where it reduced IFN activity, NF-kB mediators, cytotoxic CD8 markers, dermal inflammation following UVB exposure (model of photosensitivity), and provided a survival benefit.[89]
- **Target Indications:** The primary focus for Phase 2 is SLE, with trial initiation expected in 2025.[87] Treatment-refractory RA is also mentioned as an initial focus.[87] Ventus highlights the potential for VENT-03 across a broad range of immunological, inflammatory, and cardiometabolic diseases where cGAS is implicated, including systemic sclerosis, dermatomyositis, and Sjögren's disease.[87] The company suggests VENT-03 could impact both IFN and NF-kB pathways relevant to SLE pathology.[87]
- **Reported Results & Timelines:** The Phase 1 trial was successfully completed in October 2024.[87] VENT-03 was reported to be safe and well-tolerated at all tested dose levels, including doses exceeding those planned for Phase 2. No dose-limiting toxicities (DLTs) or serious adverse events (SAEs) were observed, and any treatment-related AEs were mild and transient.[88] The drug demonstrated a favorable PK profile supporting once-daily dosing and achieved plasma concentrations sufficient for full target inhibition, along with robust pharmacodynamic effects.[88] Ventus plans to present the full Phase 1 data at a future medical conference.[90] Initiation of the Phase 2 trial in SLE is expected in 2025.[87]

2.3. Other Clinical-Stage Programs (Contextual)

To provide context, it is useful to note clinical activity involving modulators of the downstream STING protein. Primarily, STING *agonists* have been investigated, mostly in oncology, aiming to boost anti-tumor immunity. Examples include Merck's MK-1454 (Phase 1/2 intratumoral injection study NCT03010176, terminated for strategic reasons, not safety/efficacy) [133], Aduro/Novartis' ADU-S100/MIW815 (Phase 1/2, NCT02675439, NCT03172936) [135], BMS' BMS-986301 (Phase 1, NCT03956680) [135], Boehringer Ingelheim's BI-1387446 (Phase 1, NCT04147234) [135], and Takeda's TAK-676 (intravenous, Phase 1/2, NCT04420884).[135] Pfizer also recently terminated a Phase 1 trial of an oral STING agonist, PF-07820435, citing strategic

reasons.[133] ImmuneSensor Therapeutics is also active in STING agonism with IMSA101, which completed a Phase 1/2 trial in refractory malignancies (NCT04020185) [137] and is currently in Phase 2 trials combining IMSA101 with radiotherapy and checkpoint inhibitors in oligometastatic/oligoprogressive solid tumors (NCT05846646, NCT05846659).[94]

The clinical development of STING *antagonists* for inflammatory diseases is less advanced publicly but represents a significant area of investment, notably highlighted by Novartis' acquisition of IFM Due's STING antagonist portfolio.[133]

The successful progression of both IMSB-301 and VENT-03 through initial Phase 1 hurdles represents a significant advancement for the cGAS inhibitor field. It overcomes the historical challenge of translating biochemical potency into viable clinical candidates with acceptable PK and safety, a problem that plagued earlier inhibitors like PF-06928215 which showed high biochemical affinity but poor cellular activity.[5] This achievement validates cGAS as a druggable target for inflammatory and autoimmune conditions, moving the concept beyond preclinical validation into human testing. The use of advanced discovery platforms, such as Ventus' ReSOLVE®, may have been instrumental in identifying molecules with the necessary properties to succeed where earlier attempts failed.[87]

Furthermore, the clinical strategies adopted by both ImmuneSensor and Ventus show remarkable convergence. Both companies initiated Phase 1 trials in healthy volunteers to establish safety, PK, and target engagement before moving to patient populations. Both are targeting Type I interferonopathies, with ImmuneSensor prioritizing the rare, genetically defined AGS initially, while Ventus targets the larger, more complex SLE market for its first Phase 2 study, though both acknowledge the relevance of their candidates to both conditions.[81] This shared approach suggests a consensus on the optimal path forward for this novel class: de-risk in healthy subjects, establish proof-of-mechanism (target engagement, biomarker modulation) in well-defined patient groups (AGS or biomarker-selected SLE), and aim for an oral, likely once-daily TPP suitable for chronic administration.[88] This parallel development sets up a competitive dynamic where successful execution and differentiation in Phase 1b/2 patient trials will be critical for establishing leadership.

Table 1: Clinical Trials of Small Molecule cGAS Inhibitors and Related Pathway Modulators

Drug (Company)	Target	Mechanism	Phase	Status	Indication(s)	Key Design / Endpoints	Key Results / Timeline

IMSB-301 (ImmuneSensor)	cGAS	Inhibitor (Oral)	Phase 1	Ongoing (Dosing initiated Q3/Q4 2024)	Healthy Volunteers (Initial); Planned Ph1b/2: AGS, SLE, CLE	Randomized, DB, PC; SAD/MAD; N≈64. Primary: Safety/Tolerability. Secondary: PK, Target Engagement (ex vivo assay) [81]	First SAD cohort completed, PK/exposure as predicted.[83] Full Ph1 data expected end 2024; Plan rapid transition to Ph1b/2.[83]
VENT-03 (Ventus)	cGAS	Inhibitor (Oral)	Phase 1	Completed (Oct 2024)	Healthy Volunteers (Completed); Planned Ph2: SLE (initiation 2025), potentially RA [87]	SAD/MAD; N=72. Endpoints: PK, Target Engagement, Safety, Tolerability [88]	Safe & well-tolerated; Favorable PK for OD dosing; Full target inhibition achieved; Robust PD.[90] Ph2 SLE trial planned for 2025.[88]
***PF-07820435* (Pfizer)**	STING	Agonist (Oral)	Phase 1	Terminated (Strategic reasons, Mar 2025)	Advanced Solid Tumors	N=9 enrolled [133]	Terminated Mar 2025, not due to safety/efficacy.[133]
***MK-1454* (Merck)**	STING	Agonist (Intratumoral)	Phase 1/2	Terminated (Strategic reasons)	Advanced Solid Tumors / Lymphomas (Mono & + Pembrolizumab)	Open-label, multicenter (NCT03010176) [134]	Terminated. Preclinical data showed tumor cytokine upregulation & antitumor activity.[147]
***ADU-S100/MIW815* (Aduro/Novartis)**	STING	Agonist (Intratumoral)	Phase 1/2	Active (trials ongoing/completed)	Advanced/Metastatic Solid Tumors / Lymphomas (Mono & +	Multiple trials (e.g., NCT02675439, NCT031729	Showed potential to enhance immune response,

					Spartalizumab)	36) [135]	some tumor regression reported.[135]
***IMSA101* (ImmuneSensor)**	STING	Agonist (Intratumoral)	Phase 1/2	Completed (Sep 2023)	Advanced Refractory Malignancies (Mono & + ICI)	N=40 (NCT04020185); Safety, Efficacy [137]	Phase 1 completed, demonstrated safety/efficacy.[137]
***IMSA101* (ImmuneSensor)**	STING	Agonist (Intratumoral)	Phase 2	Ongoing	Oligometastatic NSCLC/RCC (+ PULSAR + ICI); Oligoprogressive Solid Tumors (+ PULSAR + ICI)	Randomized; Safety lead-in followed by comparison vs control (PULSAR+ICI). Primary: PFS rate (NCT05846646, NCT05846659) [139]	Ongoing trials partially funded by CPRIT grant.[94]

DB: Double-Blind; PC: Placebo-Controlled; SAD: Single Ascending Dose; MAD: Multiple Ascending Dose; PK: Pharmacokinetics; PD: Pharmacodynamics; AGS: Aicardi-Goutières Syndrome; SLE: Systemic Lupus Erythematosus; CLE: Cutaneous Lupus Erythematosus; RA: Rheumatoid Arthritis; ICI: Immune Checkpoint Inhibitor; PULSAR: Personalized Ultra-fractionated Stereotactic Adaptive Radiotherapy; PFS: Progression-Free Survival.
Italicized drugs target STING (agonist) and are included for context.

3. Emerging Scientific Frontiers (2023-Present)

The cGAS inhibitor field is not static; ongoing scientific research continues to uncover novel inhibitor scaffolds and mechanisms, while simultaneously deepening the understanding of cGAS biology and its role in health and disease. Literature published since 2023 reveals significant progress on both fronts.

3.1. Novel cGAS Inhibitor Scaffolds and Mechanisms

While the lead clinical candidates IMSB-301 and VENT-03 likely act via competitive inhibition at the catalytic site where ATP and GTP bind [5], recent research has actively explored alternative modes of inhibition and diverse chemical matter. This diversification aims to overcome potential limitations of catalytic site inhibitors (e.g., competition with high endogenous

nucleotide levels, potential off-target kinase activity) and to secure distinct intellectual property positions.

- **DNA-Binding Site Interference:** Several approaches aim to prevent cGAS activation by blocking its interaction with dsDNA. Older examples include the antimalarial drug quinacrine (later shown to act indirectly via DNA conformation changes) [4] and the polyanionic drug suramin.[5] More recent examples include second-generation antimalarial derivatives like X6, reported to be more effective than hydroxychloroquine in reducing interferon-stimulated gene (ISG) expression in AGS models and SLE patient cells [9], antisense oligonucleotides (ASOs) like A151 that interact with the dsDNA binding domain [55], and cyclic peptides like XQ2B designed to block dsDNA binding.[148] This strategy bypasses the challenge of competing with high intracellular ATP/GTP concentrations.
- **Allosteric Inhibition:** This involves targeting sites distinct from the catalytic or DNA-binding domains to induce conformational changes that impair enzyme function. Examples include compounds targeting the cGAS dimerization interface or its zinc capsular structure.[148] This approach offers potential for greater selectivity compared to active site inhibitors.
- **Covalent Inhibition:** A 2023 study reported the discovery of compound **3** (1-(1-phenyl-3,4-dihydro-1*H*-pyrrolo[1,2-a]pyrazin-2-yl)prop-2-yn-1-one), identified via screening, as a covalent inhibitor of cGAS.[74] Mass spectrometry and mutagenesis confirmed that it covalently modifies Cysteine 419 (Cys419) within the cGAS protein. Compound **3** exhibited cellular potency (IC50 = 0.51 µM for inhibiting ISD-stimulated cGAS activation) superior to the known inhibitor RU.521 and demonstrated better pathway selectivity. Importantly, it showed therapeutic efficacy in a mouse model of DSS-induced colitis.[74] Covalent inhibition can offer advantages like prolonged target engagement and potentially lower required doses, but necessitates careful evaluation of selectivity to avoid off-target reactivity.
- **Phase Separation Modulation:** The process of liquid-liquid phase separation (LLPS), where cGAS molecules condense with DNA into liquid-like droplets, is increasingly recognized as crucial for efficient cGAS activation and cGAMP synthesis.[7] Targeting this process represents a novel mechanistic approach. The natural product Epigallocatechin gallate (EGCG) was found to impact DNA-induced LLPS of cGAS [55], and the cyclopeptide XQ2B also inhibits LLPS alongside DNA binding.[148]
- **Novel Scaffolds (2023+):**
    - *Pyrimidine Amides:* Ventus Therapeutics reported (in ACS Med Chem Lett, 2025) the discovery of pyrimidine amide **compound 36**.[149] This compound was identified through structure-based hybridization of two distinct inhibitor series targeting the GTP-binding site (a pyridine carboxylate HTS hit and a previously disclosed tetrahydrocarboline). Compound **36** demonstrated potent inhibition of both human and mouse cGAS isoforms and possessed a favorable PK profile in mice. It showed dose-dependent

reduction of cGAMP production in a ConA-induced liver injury model, validating its potential as an *in vivo* tool compound..[149149]

- *Natural Flavonoids:* A 2023 study screened a natural flavonoid library and identified baicalein and baicalin as novel cGAS inhibitors.[150] Crystal structures of these compounds complexed with human cGAS were solved, providing mechanistic insights. Subsequent structure-based virtual screening led to the identification of **compound C20**, which inhibited both human and mouse cGAS with low micromolar IC50 values (2.28 µM and 1.44 µM, respectively). Its binding mode was confirmed by X-ray crystallography.[150] This highlights the utility of natural product libraries and structure-based design for identifying novel inhibitor scaffolds.
- *Other Examples:* Earlier work identified butyrolactone-based inhibitors [55] and compound 14 (an AMPK inhibitor that also inhibits cGAS).[55]

The diversification of inhibitory mechanisms and chemical scaffolds beyond traditional catalytic site competition is a significant trend. It reflects efforts to overcome the limitations of early inhibitors, secure novel IP, and leverage new biological insights like the role of LLPS. The identification of a covalent inhibitor (Compound 3) and potent hybrid structures (Compound 36) in recent years underscores the continued progress in medicinal chemistry targeting cGAS. This dynamic discovery landscape suggests that next-generation inhibitors with potentially improved or distinct therapeutic profiles may emerge, challenging the current clinical frontrunners.

Table 2: Novel cGAS Inhibitor Scaffolds/Mechanisms (Reported 2023-Present)

Scaffold/Class	Mechanism	Example Compound(s)	Key Findings / Potency	Source Snippet ID
Pyrrolo[1,2-a]pyrazinone	Covalent (binds Cys419)	Compound **3** (1-(1-phenyl-3,4-dihydro-1*H*-pyrrolo[1,2-a]pyrazin-2-yl)prop-2-yn-1-one)	Cellular IC50 = 0.51 µM (ISD stim); mcGAS IC50 = 0.97 µM. More potent & selective than RU.521 in cells. Efficacious in mouse DSS colitis model. Direct binding	74

			confirmed.	
Pyrimidine Amide	Catalytic site (GTP-binding)	Compound **36** (Ventus Therapeutics)	Potent human/mouse cGAS inhibitor (nM range implied). Favorable mouse PK. Dose-dependent cGAMP reduction in ConA mouse model. Derived via structure-based hybridization.	149
Flavonoid (derived from Baicalein/Baicalin)	Catalytic site	Compound **C20**	IC50 = 2.28 µM (h-cGAS), 1.44 µM (m-cGAS). Identified via virtual screen based on baicalein/baicalin co-crystal structures. Binding mode confirmed by crystallography.	150
Flavonoid (Natural Product)	Catalytic site	Baicalein, Baicalin	Identified as novel cGAS inhibitors via screening. Co-crystal structures solved.	150
Small Molecule	STING Synergist (Enhances cGAMP activation)	Compound **67**	EC50 = 20.53 µM (synergistic effect). Binds STING-CTD. No inherent agonist	201

			activity. Potent antitumor efficacy *in vivo*. Favorable safety/PK. Developed via reverse optimization.	

Note: This table focuses on novel scaffolds/mechanisms reported 2023-present. Other mechanisms like DNA-binding interference (e.g., X6, ASOs, XQ2B) and LLPS modulation (EGCG) were also identified but may have originated slightly earlier or involve different modalities.

3.2. Significant Advances in Understanding cGAS Biology (2023+)

Parallel to inhibitor development, fundamental research continues to refine our understanding of cGAS function, regulation, and its broader biological roles. Key recent advances include:

- **Complex Regulation:** The activity of the cGAS-STING pathway is tightly controlled by multiple layers of regulation, including intricate PTM networks. Phosphorylation, acetylation, ubiquitination, methylation, palmitoylation, and glycosylation all play roles in modulating the activity, stability, and localization of cGAS and STING, thereby fine-tuning the immune response.[37] Specific ubiquitin ligases (e.g., TRIM56, TRAF6) and deubiquitinases (e.g., USP21) have been identified that modify cGAS or STING to either promote activation/stability or target them for degradation.[47] For instance, TRIM56-mediated monoubiquitination enhances cGAS dimerization and DNA binding.[47] Negative regulators like ZNF593 have also been identified, which attenuate cGAS activation by interfering with DNA binding.[68] Structural studies are providing insights into autoinhibitory mechanisms.[48] This complex regulation underscores the need for precise therapeutic modulation.
- **Nuclear cGAS Functions:** While initially characterized as a cytosolic sensor, it is now clear that cGAS also resides in the nucleus, where it exhibits distinct functions and regulation.[7] Nuclear cGAS is tightly associated with chromatin, particularly nucleosomes containing histones H2A/H2B, which prevents its activation by abundant self-DNA under homeostatic conditions.[19] However, nuclear cGAS can be activated under specific circumstances, such as by nuclear pathogens (e.g., HIV interaction with NONO [19]) or potentially during specific cell cycle phases or DNA damage events. It has been implicated in regulating DNA damage repair (reportedly inhibiting homologous recombination by interacting with PARP1 [19]) and stabilizing DNA replication forks.[19] In certain cell types like dendritic cells, nuclear cGAS can synthesize cGAMP and contribute to innate immune activation.[19] Viruses have evolved

mechanisms to specifically target nuclear cGAS, such as the Seneca Valley virus 3C protease which translocates to the nucleus, binds DNA, and cleaves both cGAS and histone H2A to impair cGAS translocation and immune signaling.[19]

- **DNA Sensing Nuances:** cGAS generally requires dsDNA longer than ~45 base pairs for efficient activation, although shorter fragments (<20 bp) can bind but activate less efficiently.[20] While largely sequence-independent, cGAS preferentially binds certain DNA structures like bent DNA or incomplete nucleoids.[10] Recent work suggests mechanisms may exist for discriminating self vs. non-self DNA, potentially involving DNA condensation mediated by polyamines like spermine, which enhances cGAS binding to naked (e.g., viral) DNA but not chromatinized DNA.[10]
- **Integration with Cellular Processes:** The links between cGAS-STING signaling and fundamental cellular processes are becoming clearer. The pathway is interconnected with autophagy, senescence, various forms of programmed cell death (apoptosis, pyroptosis, necroptosis), cellular metabolism, and even translation regulation.[1] For example, STING translocation can directly induce autophagy independently of canonical pathways [20], while cGAS itself has been implicated in promoting mitotic cell death.[7]
- **Broadening Disease Relevance:** Research continues to strengthen the association of cGAS-STING dysregulation with an expanding list of human diseases. Beyond the core autoimmune/inflammatory conditions, strong links are being established or reinforced in neurodegenerative diseases (AD, PD, ALS, HD) [1], cancer (where the pathway has dual roles, promoting anti-tumor immunity but also potentially driving metastasis or resistance) [15], aging [1], cardiovascular diseases [1], metabolic diseases (NASH, diabetes) [1], ocular inflammation (AMD, diabetic retinopathy, uveitis) [1], liver diseases (viral hepatitis, ALD, MASLD) [6], and kidney diseases.[1]

The growing appreciation of cGAS's roles beyond simple cytoplasmic IFN induction, particularly its nuclear functions and connections to processes like DNA repair, autophagy, and senescence, adds layers of complexity to its therapeutic targeting. While inhibiting the canonical inflammatory pathway is the primary goal for autoimmune diseases, the broader consequences of systemic cGAS inhibition need careful consideration. These non-canonical functions might offer additional therapeutic benefits in certain contexts (e.g., modulating senescence in aging-related diseases) but could also pose risks (e.g., interfering with necessary DNA repair in other situations). The dual role observed in cancer, where cGAS-STING can promote anti-tumor immunity but also potentially drive metastasis or immune evasion [15], further complicates therapeutic strategies in oncology and highlights the context-dependent nature of the pathway's outcomes. Understanding these multifaceted roles is crucial for predicting the full spectrum of effects of cGAS inhibitors and for identifying the most appropriate disease settings and patient populations for intervention.

4. Business Development and Competitive Dynamics (2020-Present)

The therapeutic potential of modulating the cGAS-STING pathway has attracted significant attention from both venture capital and established pharmaceutical companies, leading to substantial funding rounds, strategic collaborations, and acquisitions, particularly since 2020.

4.1. Key Players & Funding

Several companies are actively developing small molecule modulators targeting the cGAS-STING pathway, with ImmuneSensor Therapeutics and Ventus Therapeutics emerging as clinical-stage leaders in the cGAS inhibitor space.

- **ImmuneSensor Therapeutics:** Founded in 2014 based on Dr. Zhijian Chen's foundational discoveries at UT Southwestern [84], ImmuneSensor is pursuing a dual strategy targeting both cGAS inhibition for inflammatory/autoimmune diseases (with lead candidate IMSB-301) and STING agonism for oncology (with IMSA101, currently in Phase 2).[84] The company is relatively small (~10 employees [158]) and has secured funding primarily through grants and potentially earlier VC rounds. Notably, it received a $16.1 million Product Development Research Grant from the Cancer Prevention and Research Institute of Texas (CPRIT) in September 2022 to support Phase 2 development of its STING *agonist* IMSA101.[94] In December 2022, Pitchbook data indicates a $10M Later Stage VC (Series A) funding round.[158]
- **Ventus Therapeutics:** Established in 2019 [110], Ventus has rapidly progressed multiple programs by leveraging its proprietary ReSOLVE® platform, which integrates structural biology, biophysics, and computational chemistry for structure-based drug design.[87] The company has raised significant capital: $60M Series A in May 2020 [119], $100M Series B in January 2021 [119], and $140M Series C in February 2022, co-led by SoftBank Vision Fund 2 and RA Capital Management.[119] Its total funding exceeds $300M.[110] Ventus' pipeline includes the cGAS inhibitor VENT-03 and two NLRP3 inhibitors: VENT-01 (peripheral, licensed to Novo Nordisk) and VENT-02 (brain-penetrant, in Phase 2 for Parkinson's).[87] Ventus has also received grant funding, including a DoD grant for lupus research (May 2022) [119] and a Michael J. Fox Foundation grant for an NLRP3 PET tracer (April 2023).[119]
- **IFM Therapeutics / IFM Due:** IFM Therapeutics operates via a subsidiary model, housing distinct programs in separate entities financed by investors including Atlas Venture, Abingworth, and Novartis.[141] IFM Due was established in February 2019 specifically to develop small molecule antagonists/inhibitors of the cGAS-STING pathway for inflammatory diseases.[60]
- **Nudge Therapeutics / BellBrook Labs:** Nudge Therapeutics focuses on developing preclinical cGAS inhibitors.[164] It shares leadership with BellBrook Labs (Robert Lowery is

CEO of both) [164], which is known for developing high-throughput screening assays for drug discovery, including assays relevant to the cGAS-STING pathway.[5]

- **Large Pharma:** Several major pharmaceutical companies, including Novartis, Merck, Pfizer, Roche, GSK, and Janssen, have patent filings related to cGAS or STING modulators, although many of these relate to STING *agonists* for oncology rather than cGAS inhibitors for inflammation.[4]

4.2. Key Deals & Collaborations (2020-Present)

The period from 2020 onwards has witnessed several significant transactions shaping the competitive dynamics:

- **Novartis Acquires IFM Due (Option Exercised March 2024):** This is a landmark deal in the STING antagonist space. Following a four-year research collaboration initiated in September 2019 (extended in Dec 2021 [163]), where Novartis fully funded IFM Due's R&D on cGAS-STING inhibitors/antagonists [141], Novartis exercised its option to acquire the subsidiary. The deal involves a $90 million upfront payment, with potential milestones bringing the total consideration up to $835 million.[133] This gives Novartis full rights to IFM Due's portfolio of STING antagonists for treating inflammation-driven diseases.[133] This follows Novartis' earlier acquisition of IFM Tre (NLRP3 antagonists) in 2019 and BMS' acquisition of IFM's STING/NLRP3 agonist programs in 2017, highlighting IFM's successful subsidiary model.[60]
- **Veralox Therapeutics Option to Acquire Nudge Therapeutics (January 2025):** Veralox, a clinical-stage company focused on a 12-LOX inhibitor (VLX-1005) for HIT [164], secured an exclusive option to acquire Nudge Therapeutics and its preclinical cGAS inhibitor program.[164] The acquisition is triggered by achieving downstream milestones; financial terms were not disclosed.[164] This deal allows Veralox to leverage its expertise (potentially linked to the shared leadership with BellBrook Labs) and expand into the cGAS inhibitor space, complementing its focus on autoimmune and inflammatory diseases.[164]
- **Ventus Therapeutics Licenses Peripheral NLRP3 Inhibitor (VENT-01) to Novo Nordisk (September 2022):** While not directly involving cGAS inhibitors, this deal is significant for Ventus. Novo Nordisk gained exclusive worldwide rights to develop and commercialize VENT-01 for diseases including MASH, CKD, and other cardiometabolic disorders.[119] Ventus received $70 million upfront and is eligible for up to $633 million in milestones plus royalties.[128] This partnership provided substantial non-dilutive funding for Ventus and validated its ReSOLVE® platform, allowing Ventus to focus on its wholly-owned brain-penetrant NLRP3 (VENT-02) and cGAS (VENT-03) programs.[128] Novo Nordisk initiated a Phase 1 trial for the licensed compound (now NNC6022-0001) in May 2024.[124]
- **General Industry Trends:** The broader biopharma landscape anticipates increased M&A

and licensing activity in 2025, driven partly by major patent expirations facing large companies (e.g., Merck's Keytruda, BMS' Opdivo/Eliquis) creating pipeline gaps.[186] There is also a notable trend of increased in-licensing of assets originating from China [188], and continued interest in deals involving AI-driven drug discovery platforms.[186]

4.3. Strategic Implications

The business development activities highlight several key strategic points:

- **Validation and Investment:** The substantial venture funding secured by Ventus and the major acquisition of IFM Due by Novartis underscore the high level of scientific and commercial validation for targeting innate immune pathways like cGAS-STING and NLRP3 for inflammatory diseases. Investors and pharmaceutical companies see significant therapeutic potential and market opportunity.
- **Pathway Versatility:** The concurrent development of pathway *inhibitors* for inflammatory/autoimmune diseases (e.g., IMSB-301, VENT-03, IFM Due's STING antagonists) and pathway *agonists* for oncology (e.g., IMSA101, multiple STING agonists from large pharma) demonstrates the therapeutic versatility of targeting the cGAS-STING axis. The market clearly distinguishes between these opposing modulation strategies for different therapeutic areas.
- **Platform Value Proposition:** Ventus' ability to raise significant capital and secure a lucrative licensing deal for its NLRP3 program strongly suggests that investors and partners place high value on advanced drug discovery platforms, like ReSOLVE®, capable of tackling historically "undruggable" or challenging targets within the innate immunity space.[120] Platforms that demonstrably accelerate the identification and optimization of high-quality small molecules for these complex intracellular targets are likely to continue attracting investment.
- **Emergence of New Players:** The Veralox/Nudge deal indicates that the cGAS inhibitor field is not solely dominated by the current clinical leaders. Smaller companies, potentially leveraging specialized assays or focused discovery efforts, are entering the space, suggesting a pipeline of earlier-stage assets exists.

A key strategic divergence is evident in the approaches to pathway inhibition. While Ventus and ImmuneSensor are directly targeting the upstream sensor cGAS, Novartis' acquisition of IFM Due represents a major commitment to inhibiting the downstream adaptor protein STING. Inhibiting cGAS offers the potential advantage of blocking the pathway at its initiation point, preventing all downstream consequences of cGAMP production. Conversely, STING inhibition targets a central signaling hub but might allow for cGAMP production (potentially relevant if cGAMP has other roles) and could be influenced by different STING haplotypes or activation

mechanisms. The choice between these targets likely reflects differing assessments of druggability, specificity, potential safety profiles, and intellectual property considerations. The clinical success (or failure) of these parallel strategies in specific disease contexts will be highly informative for the field and will shape future development efforts.

Table 3: Key Business Development Activities for Small Molecule cGAS/STING Inhibitors (2020-Present)

Date	Companies Involved	Deal Type	Asset(s)/Focus	Deal Value (Upfront/Total/Milestones)	Key Strategic Implication
Mar 2024	Novartis / IFM Therapeutics (IFM Due)	M&A (Option Exercise)	STING Antagonist Program (Inflammatory Diseases)	$90M / $835M / $745M [141]	Major pharma commitment to STING antagonism as alternative to cGAS inhibition for inflammation. Culmination of 4-year R&D collaboration.
Jan 2025	Veralox Therapeutics / Nudge Therapeutics	Option to Acquire	Preclinical cGAS Inhibitor Program	Undisclosed (Milestone-based acquisition) [164]	Smaller player (Veralox) enters cGAS space via option deal, potentially leveraging Nudge/BellBrook Labs expertise. Expands Veralox pipeline focus.

Sep 2022	Ventus Therapeutics / Novo Nordisk	Exclusive License	VENT-01 (Peripheral NLRP3 Inhibitor Program)	$70M / $703M / $633M + Royalties [128]	Validates Ventus' platform for related innate immunity target (NLRP3). Provides non-dilutive funding. Allows Ventus to focus on cGAS/CNS NLRP3.
Feb 2022	Ventus Therapeutics	Funding (Series C)	ReSOLVE® Platform, cGAS & NLRP3 Inhibitor Pipeline	$140M [119]	Significant funding to scale platform and advance multiple programs (incl. VENT-03) towards/into clinic. Led by SoftBank Vision Fund 2, RA Capital.
Dec 2022	ImmuneSensor Therapeutics	Funding (Later Stage VC / Series A)	cGAS Inhibitor (IMSB-301) & STING Agonist Programs	$10M [158]	Funding secured (potentially Series A) to advance clinical programs.
Sep 2022	ImmuneSensor Therapeutics / CPRIT	Grant	IMSA101 (STING Agonist Phase 2	$16.1M [94]	Non-dilutive funding specifically for STING *agonist*

			Development)		oncology program, supporting the company's dual strategy.
Jan 2021	Ventus Therapeutics	Funding (Series B)	ReSOLVE® Platform, cGAS & NLRP3 Inhibitor Pipeline	$100M [119]	Major funding round to advance discovery platform and pipeline programs.
May 2020	Ventus Therapeutics	Funding (Series A)	Launch, Platform & Pipeline Development	$60M [119]	Company launch with significant Series A led by Versant Ventures, GV participation.
Sep 2019	Novartis / IFM Therapeutics (IFM Due)	Option & Collaboration	cGAS-STING Inhibitor/Antagonist Program	R&D Funding + Option for $835M total [141]	Initial deal setting up the later acquisition. Novartis funded IFM Due's preclinical work.

Note: Deals involving STING agonists or NLRP3 inhibitors are included for key players (ImmuneSensor, Ventus) or major transactions (Novartis/IFM Due) to provide context on company strategy and overall pathway interest.

5. Inferred Target Product Profiles (TPPs) for Leading cGAS Inhibitors

Based on publicly available information, including preclinical data, clinical trial designs, company communications, and the known pathobiology of target diseases, potential Target

Product Profiles (TPPs) can be inferred for the leading clinical-stage cGAS inhibitors, IMSB-301 and VENT-03. These TPPs outline the likely characteristics and intended positioning of these drug candidates.

5.1. IMSB-301 (ImmuneSensor Therapeutics)

- **Target Indications:**
  - *Initial:* Aicardi-Goutières Syndrome (AGS), a rare, severe Type I interferonopathy with a strong genetic link to the cGAS pathway.[104] Also targeting defined patient populations within Cutaneous Lupus Erythematosus (CLE) and Systemic Lupus Erythematosus (SLE) in early patient studies.[104]
  - *Potential Expansion:* Broader SLE populations, other Type I interferonopathies (e.g., COPA syndrome mentioned generally for the pathway [1]), and potentially other conditions characterized by cGAS-driven inflammation such as diabetic kidney disease, age-related macular degeneration (AMD), and other autoimmune disorders.[81]
- **Administration & Dosing:** Oral formulation.[80] Dosing frequency likely aimed at once or twice daily for chronic conditions; the Phase 1 MAD protocol uses twice-daily (BID) dosing.[81]
- **Mechanism & Selectivity:** Designed as a potent and specific inhibitor of the cGAS enzyme, blocking its catalytic activity to prevent cGAMP synthesis and subsequent STING activation and inflammatory signaling.[81]
- **Potential Differentiation:** Positioned as potentially "best-in-class" [81], leveraging foundational science from Dr. Chen's lab. Strong preclinical efficacy demonstrated in a relevant genetic model of AGS (rescue of phenotype and mortality).[81] Strategic initial focus on AGS, a rare disease with high unmet need and clear pathway involvement, supported by FDA Orphan Drug and Rare Pediatric Disease Designations, offering regulatory advantages and a potential Priority Review Voucher.[104]

5.2. VENT-03 (Ventus Therapeutics)

- **Target Indications:**
  - *Initial:* Systemic Lupus Erythematosus (SLE), with Phase 2 initiation planned for 2025.[87] Also mentioned as an initial focus: treatment-refractory Rheumatoid Arthritis (RA).[87]
  - *Potential Expansion:* Broad potential across autoimmune and inflammatory diseases (e.g., Systemic Sclerosis, Dermatomyositis, Sjögren's disease explicitly mentioned as cGAS-driven [88]) and cardiometabolic diseases.[88]
- **Administration & Dosing:** Oral formulation.[87] Phase 1 PK results support convenient once-daily dosing.[88]
- **Mechanism & Selectivity:** A potent and selective small molecule inhibitor of cGAS.[87]

Preclinical data suggests impact on both Type I IFN and NF-kB driven mediators.[87]

- **Potential Differentiation:** First-in-class cGAS inhibitor to successfully complete Phase 1 clinical development.[88] Positioned as potentially "best-in-class".[87] Developed using the advanced ReSOLVE® computational and structural biology platform, potentially conferring optimized drug-like properties.[87] Demonstrated full target inhibition and robust pharmacodynamics in Phase 1.[90] Strong preclinical efficacy in the Trex1-/- mouse model, including survival benefit and reduction of photosensitivity, relevant to SLE/AGS.[89] Direct entry into the larger SLE market planned for Phase 2.

The inferred TPPs for both IMSB-301 and VENT-03 strongly converge on the desirable profile of an oral, likely once-daily, small molecule inhibitor for treating chronic autoimmune and inflammatory diseases. This shared objective reflects the significant market need for convenient, effective therapies in conditions like SLE, where current options may involve injections or broader immunosuppression.[90] The successful demonstration of suitable PK profiles in Phase 1 by both companies [88] is a critical achievement enabling this TPP. Consequently, future competition in this class will likely focus on demonstrating superior efficacy and safety, potentially in specific patient subgroups, rather than fundamental differences in administration route or dosing frequency.

However, the initial clinical strategies diverge. ImmuneSensor's decision to target the rare, genetically defined disease AGS first, supported by ODD/RPDD designations [104], represents a common strategy for validating novel mechanisms in a context where the target pathway's role is unambiguous.[81] Success in AGS would provide strong proof-of-concept and potentially de-risk subsequent development in the more complex and heterogeneous SLE population. Ventus, conversely, is targeting the larger SLE market directly in Phase 2, perhaps reflecting confidence from their Phase 1 data and preclinical models mimicking SLE features.[89] This phased (rare-to-common) versus direct-to-common approach highlights different risk-reward calculations and development philosophies. The outcomes of these initial patient trials will be crucial in validating not only the specific drug candidates but also these differing strategic pathways for bringing cGAS inhibitors to market.

Table 4: Inferred Target Product Profiles (TPPs) for Leading cGAS Inhibitors

Feature	IMSB-301 (ImmuneSensor Therapeutics)	VENT-03 (Ventus Therapeutics)

Target Indication(s) - Initial	AGS (Primary Ph1b/2 focus); Defined subsets of CLE/SLE [104]	SLE (Planned Ph2 2025); Potentially treatment-refractory RA [87]
Target Indication(s) - Expansion	Broader SLE, other Type I interferonopathies, diabetic kidney disease, AMD, other autoimmune/inflammatory disorders [81]	Broad autoimmune/inflammatory diseases (Systemic Sclerosis, Dermatomyositis, Sjogren's), cardiometabolic diseases [87]
Route of Administration	Oral [80]	Oral [87]
Dosing Frequency	Likely Once or Twice Daily (Phase 1 MAD is BID) [81]	Once Daily (Supported by Phase 1 PK) [88]
Mechanism	Potent, specific cGAS enzyme inhibitor (prevents cGAMP production) [81]	Potent, selective cGAS inhibitor; impacts IFN & NF-kB pathways [87]
Potential Differentiation	"Best-in-class" potential; Strong preclinical AGS model efficacy; Founder expertise; Initial rare disease focus (AGS); FDA ODD/RPDD for AGS [104]	First-in-class to complete Phase 1; "Best-in-class" potential; Developed via ReSOLVE® platform; Demonstrated full target inhibition in Ph1; Strong preclinical Trex1-/- model efficacy; Direct Phase 2 entry into SLE market [87]

6. Regulatory Designations and Pathway

Regulatory designations from agencies like the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) can significantly impact the development trajectory and commercial potential of novel therapeutics, particularly those targeting rare diseases or conditions with high unmet medical need.

6.1. Confirmed Designations for cGAS Inhibitors

- **IMSB-301 (ImmuneSensor Therapeutics):** In November 2024, ImmuneSensor announced that the FDA granted both Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation (RPDD) for IMSB-301 specifically for the treatment of Aicardi-Goutières Syndrome (AGS).[104]
- **VENT-03 (Ventus Therapeutics):** Based on the available information, there are no reports of VENT-03 having received ODD, RPDD, Fast Track, or PRIME designations from the FDA or EMA for its target indications, including SLE.[192]

6.2. Implications of ODD and RPDD for IMSB-301

The designations secured by ImmuneSensor for IMSB-301 in AGS carry significant strategic weight:

- **Orphan Drug Designation (ODD):** Granted for therapies targeting rare diseases affecting fewer than 200,000 people in the US (or meeting other criteria related to development cost recovery).[82] ODD provides benefits such as potential tax credits for qualified clinical trials, waiver of FDA application fees (e.g., PDUFA fees), and, crucially, eligibility for 7 years of market exclusivity in the US upon approval for the designated orphan indication (AGS).[82] Similar incentives exist under the EMA's orphan designation framework.[166]
- **Rare Pediatric Disease Designation (RPDD):** Granted for drugs targeting serious or life-threatening diseases that primarily affect individuals aged 18 or younger and impact fewer than 200,000 people in the US.[82] The primary benefit of RPDD is the potential eligibility for a Priority Review Voucher (PRV) upon FDA approval of the drug for the designated rare pediatric disease.[80] A PRV entitles the holder to priority review (typically a 6-month review target vs. 10 months standard) for a subsequent marketing application for a different product. These vouchers are transferable and can be sold to other companies, often commanding prices in the tens to hundreds of millions of dollars, providing a significant potential source of non-dilutive funding or strategic leverage.

6.3. Potential Applicability of Expedited Pathways

Beyond ODD/RPDD, other expedited pathways might be relevant for cGAS inhibitors targeting serious conditions with unmet needs:

- **Fast Track Designation (FDA):** This designation is intended to facilitate the development and expedite the review of drugs intended to treat serious conditions and demonstrate the potential to address an unmet medical need.[117] Both AGS (a severe, often fatal condition with no cure [82]) and SLE (a chronic, systemic autoimmune disease with significant morbidity and limited treatment options for many patients [11]) could qualify based on seriousness and unmet need. Demonstrating potential to address unmet need could involve showing superiority over available therapies, improved safety, or fulfilling a need in

a specific patient subset. Fast Track allows for more frequent interactions with the FDA and eligibility for Rolling Review, where completed sections of the New Drug Application (NDA) can be submitted before the entire application is finalized.[192] While plausible, no Fast Track designations have been reported for IMSB-301 or VENT-03 in the reviewed materials.

- **PRIME (Priority Medicines) Designation (EMA):** This scheme offers enhanced regulatory support, including early dialogue and scientific advice, to developers of medicines that target an unmet medical need and offer a potential major therapeutic advantage over existing treatments or benefit patients with no treatment options. Similar to Fast Track, eligibility for cGAS inhibitors would depend on the strength of clinical data demonstrating significant benefit in serious conditions like AGS or SLE.

The regulatory strategy pursued by ImmuneSensor, securing both ODD and RPDD for IMSB-301 in AGS, directly aligns with their clinical development plan prioritizing this rare interferonopathy. This approach leverages the incentives designed to encourage development for rare diseases, providing potential market exclusivity and the valuable prospect of a PRV.[82] This validation can significantly enhance the program's value and potentially attract further investment or partnerships. It sets a clear precedent for other developers targeting rare, genetically defined interferonopathies with cGAS inhibitors.

For the broader indication of SLE, the pathway to expedited designations like Fast Track or PRIME appears plausible but hinges on demonstrating a significant advantage over existing therapies. SLE remains a disease with substantial unmet need, despite recent approvals of targeted biologics (e.g., anti-IFNAR, anti-BAFF).[90] If an oral cGAS inhibitor like VENT-03 or IMSB-301 can show compelling efficacy (potentially by addressing both IFN and NF-kB pathways [87]) and a favorable safety profile compared to current standards of care (which often include immunosuppressants with side effects [11]), it could qualify for these programs. Achieving such designations would be a significant catalyst, potentially shortening development timelines and increasing the commercial attractiveness for the large SLE market.

Table 5: Regulatory Designations for cGAS Inhibitors

Drug (Company)	Designation	Agency	Indication	Status / Date Granted
IMSB-301	Orphan Drug	FDA	Aicardi-Goutières	Granted (Nov

(ImmuneSensor)	Designation (ODD)		Syndrome (AGS)	2024) [82]
IMSB-301 (ImmuneSensor)	Rare Pediatric Disease Designation (RPDD)	FDA	Aicardi-Goutières Syndrome (AGS)	Granted (Nov 2024) [82]
IMSB-301 (ImmuneSensor)	Fast Track / PRIME	FDA/EMA	AGS / SLE / CLE	No information found
VENT-03 (Ventus)	ODD / RPDD / Fast Track / PRIME	FDA/EMA	SLE / RA / Other Autoimmune Dis.	No information found [192]
VLX-1005 (Veralox)	Orphan Drug Designation	FDA	Heparin-Induced Thrombocytopenia (HIT) / PF4 Disorders	Granted [166]
VLX-1005 (Veralox)	Fast Track Designation	FDA	Heparin-Induced Thrombocytopenia (HIT) / PF4 Disorders	Granted [166]
VLX-1005 (Veralox)	Orphan Drug Status	EMA	Heparin-Induced Thrombocytopenia (HIT) / PF4 Disorders	Granted [166]
Rilzabrutinib (Sanofi)	Orphan Drug Designation	FDA	IgG4-related disease; wAIHA	Granted (Apr 2025) [198]
Rilzabrutinib (Sanofi)	Fast Track Designation	FDA	Immune Thrombocytopenia (ITP)	Granted [198]

Note: Designations for VLX-1005 (12-LOX inhibitor) and Rilzabrutinib (BTK inhibitor) are included as recent examples of relevant designations in the autoimmune/inflammatory space mentioned

in snippets discussing cGAS inhibitors or related deals.

---

7. Strategic Outlook and Recommendations

7.1. Synthesis of Competitive Landscape

The small molecule cGAS inhibitor field has reached a critical juncture. After years of preclinical research overcoming significant medicinal chemistry hurdles [5], the target is now clinically validated as druggable. Two lead oral candidates, ImmuneSensor's IMSB-301 and Ventus' VENT-03, have successfully completed initial Phase 1 studies, demonstrating acceptable safety and PK profiles, with VENT-03 also reporting achievement of full target inhibition levels.[83] Both companies are now preparing for Phase 1b/2 patient trials, primarily targeting the Type I interferonopathies AGS and/or SLE.[81]

The scientific landscape remains highly active, with ongoing exploration of novel inhibitor scaffolds (e.g., pyrimidine amides, flavonoids, covalent inhibitors) and mechanisms (DNA-binding site, allosteric, LLPS modulation).[55] Furthermore, the understanding of cGAS biology continues to expand, revealing complex regulation and non-canonical nuclear functions with potential implications for therapeutic targeting.[16]

Commercial interest is strong, reflected in substantial VC investments (particularly for Ventus [119]) and significant strategic moves by large pharma. Novartis' potential $835M acquisition of IFM Due for its STING *antagonist* program establishes a key competitive or complementary approach targeting the same pathway.[133] The Veralox/Nudge deal suggests opportunities exist for earlier-stage assets as well.[164] Regulatory advantages, such as the ODD and RPDD secured by ImmuneSensor for IMSB-301 in AGS, further shape the strategic landscape.[104]

7.2. Key Opportunities

- **First/Best-in-Class in Interferonopathies:** A clear opportunity exists to deliver the first targeted therapy for rare, severe interferonopathies like AGS, where the cGAS pathway is the primary driver. Success here offers potential for expedited development via orphan pathways and significant clinical impact.
- **Differentiated Oral Therapy for SLE:** Given the limitations of current SLE treatments (injectable biologics, broad immunosuppressants) [11], a potent and selective oral cGAS inhibitor with a favorable safety profile could capture significant market share, particularly if efficacy can be demonstrated in specific patient subsets (e.g., those with a high IFN-I signature [12]).
- **Expansion Potential:** Positive proof-of-concept in initial indications could unlock

development across a wide range of other diseases linked to cGAS-STING dysregulation, including other autoimmune conditions (RA, Sjogren's, SSc, DM), neurodegenerative disorders (AD, PD, ALS), metabolic diseases (NASH, diabetic kidney disease), and potentially aging-related inflammation.[1]

- **Next-Generation Inhibitors:** The ongoing scientific exploration of novel mechanisms (covalent, allosteric, DNA-binding, LLPS modulation) and scaffolds presents opportunities to develop follow-on inhibitors with potentially improved efficacy, selectivity, PK/PD properties, or suitability for specific disease contexts or delivery systems.[55]

7.3. Key Challenges & Risks

- **Demonstrating Clinical Benefit:** The most significant hurdle is translating promising preclinical data and biomarker modulation (e.g., reduction in IFN signature) into tangible clinical improvements in complex, heterogeneous diseases like SLE. Clear efficacy signals in Phase 1b/2 patient trials are crucial.
- **Long-Term Safety:** As cGAS plays a fundamental role in innate immunity against pathogens and potentially in other cellular processes like DNA repair and senescence [7], the long-term consequences of chronic cGAS inhibition need careful evaluation. Potential risks include increased susceptibility to certain infections or unforeseen effects related to non-canonical functions.
- **Competitive Landscape:** The lead cGAS inhibitors face direct competition from each other. Furthermore, STING antagonists (pursued by Novartis/IFM Due) represent a significant alternative strategy for pathway inhibition. Competition also exists from therapies targeting downstream effectors (e.g., IFNAR blockers, JAK inhibitors) or employing different modalities.
- **Patient Stratification:** The heterogeneity of diseases like SLE means that cGAS inhibition may only be effective in specific patient subsets. Identifying predictive biomarkers (e.g., IFN signature [12]) and effectively stratifying patients in clinical trials will likely be critical for success, but adds complexity to trial design and execution.

7.4. Recommendations for Strategic Positioning & Future Development

Based on the current landscape, the following strategic considerations are recommended for companies involved in cGAS inhibitor development:

1. **Prioritize Flawless Clinical Execution:** The immediate focus must be on successfully executing Phase 1b/2 trials for IMSB-301 and VENT-03. Generating robust safety and efficacy data in the initial target patient populations (AGS and/or SLE) is paramount to establish clinical proof-of-concept and differentiate the leading candidates. Timeliness is also critical in this competitive race.

2. **Leverage Biomarker Strategies:** Incorporate validated biomarkers, such as IFN gene signatures [12] or pathway-specific pharmacodynamic markers (e.g., *ex vivo* cGAMP production assays [81]), into clinical trial designs. These can aid in patient selection, confirm target engagement *in vivo*, demonstrate pharmacodynamic effects, and potentially serve as surrogate endpoints to accelerate development, particularly in rare diseases like AGS.
3. **Seek Differentiation:** Beyond establishing basic safety and efficacy, companies should actively seek points of differentiation. This could involve demonstrating superior efficacy or safety compared to competitors or standard-of-care, identifying specific patient subsets who derive maximal benefit, showing efficacy against particular disease manifestations (e.g., cutaneous vs. systemic lupus), or exploring potential combination therapies with complementary mechanisms.
4. **Monitor Scientific and Competitive Intelligence:** The rapid pace of scientific discovery necessitates continuous monitoring of emerging cGAS biology (e.g., nuclear roles, regulation) and novel inhibitor mechanisms/scaffolds. This intelligence is crucial for identifying potential next-generation opportunities and anticipating competitive threats from alternative approaches like STING antagonism or downstream pathway modulation.
5. **Contextualize within Pathway Modulation:** Evaluate the positioning of cGAS inhibitors relative to STING antagonists and other pathway modulators. Understand where each approach might offer advantages (e.g., specificity, safety) in different disease contexts. Consider potential future combination strategies that target multiple nodes in the pathway or complementary pathways.
6. **Optimize Strategic Partnerships:** For clinical-stage companies like ImmuneSensor and Ventus, strategic partnerships could provide resources to accelerate broader development programs (e.g., expansion into multiple indications) or access commercial infrastructure. For companies with novel preclinical assets (like Nudge/Veralox or those developing next-gen mechanisms), collaborations or licensing deals with larger partners will be crucial for validation and funding further development. The high value placed on platform technologies like Ventus' ReSOLVE® [120] suggests highlighting such capabilities is key in partnership discussions.

In conclusion, the small molecule cGAS inhibitor field is poised for significant progress, transitioning from preclinical promise to clinical evaluation. While substantial opportunities exist, particularly in interferon-driven autoimmune diseases, successful navigation of clinical development challenges, differentiation from competitors (including STING antagonists), and careful consideration of the complex underlying biology will be essential for realizing the therapeutic potential of this exciting target class.

Works cited

1. Leveraging the cGAS-STING Pathway - ImmuneSensor Therapeutics, accessed April 30, 2025, https://www.immunesensor.com/science/cgas-sting-pathway/
2. cGAS - The long awaited cytosolic DNA sensor | Review - InvivoGen, accessed April 30, 2025, https://www.invivogen.com/review-cgamp
3. Control of innate immunity by the cGAS-STING pathway - PubMed, accessed April 30, 2025, https://pubmed.ncbi.nlm.nih.gov/35485309/
4. WO2023154962A1 - Cgas inhibitors and uses thereof - Google ..., accessed April 30, 2025, https://patents.google.com/patent/WO2023154962A1/en
5. Development of human cGAS-specific small-molecule inhibitors for repression of dsDNA-triggered interferon expression, accessed April 30, 2025, https://www.regenhealthsolutions.info/wp-content/uploads/2019/06/Development-of-human-cGAS-specific-smallmolecule-inhibitors-for-repression-of-dsDNAtriggered-interferon-expression.pdf
6. patentimages.storage.googleapis.com, accessed April 30, 2025, https://patentimages.storage.googleapis.com/07/d9/01/b2d670c5b59d05/AU2022273980A1.pdf
7. Biochemistry, Cell Biology, and Pathophysiology of the Innate ..., accessed April 30, 2025, https://www.annualreviews.org/doi/10.1146/annurev-biochem-040320-101629
8. Intervention of cGAS–STING signaling in sterile inflammatory diseases - Oxford Academic, accessed April 30, 2025, https://academic.oup.com/jmcb/article/14/2/mjac005/6515952
9. Updated roles of cGAS-STING signaling in autoimmune diseases ..., accessed April 30, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10538533/
10. cGAS: action in the nucleus - Frontiers, accessed April 30, 2025, https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1380517/full
11. WO2019153002A1 - 2,3,4,5-tetrahydro-1h-pyrido[4, 3-b]indole inhibitors of cgas for treating autoinflammatory diseases - Google Patents, accessed April 30, 2025, https://patents.google.com/patent/WO2019153002A1/en
12. cGAS INHIBITORS - Justia Patents, accessed April 30, 2025, https://patents.justia.com/patent/20240246979
13. The cGAS-STING pathway as a therapeutic target in inflammatory ..., accessed April 30, 2025, https://pubmed.ncbi.nlm.nih.gov/33833439/
14. Research Summary: August 2024 - Alex - The Leukodystrophy Charity, accessed April 30, 2025, https://alextlc.org/research/research-summary-august-2024/
15. Agonists and Inhibitors of the cGAS-STING Pathway - MDPI, accessed April 30, 2025, https://www.mdpi.com/1420-3049/29/13/3121
16. multifaceted functions of cGAS | Journal of Molecular Cell Biology - Oxford Academic, accessed April 30, 2025, https://academic.oup.com/jmcb/article/14/5/mjac031/6583286
17. Polyvalent Design in the cGAS-STING Pathway - PMC, accessed April 30, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8792294/
18. Regulation and inhibition of the DNA sensor cGAS - PMC - PubMed Central, accessed April 30, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7726805/
19. Viral protease binds to nucleosomal DNA and cleaves nuclear cGAS that attenuates type I

interferon - PMC, accessed April 30, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11980361/
20. Regulation of cGAS and STING signaling during inflammation and infection - PMC, accessed April 30, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10316007/
21. The cGAS-STING pathway in atherosclerosis - Frontiers, accessed April 30, 2025, https://www.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2025.1550930/full
22. cGAS Mediates the Inflammatory Responses of Human Microglial Cells to Genotoxic DNA Damage - PMC - PubMed Central, accessed April 30, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11073916/
23. STING in tumors: a focus on non-innate immune pathways - Frontiers, accessed April 30, 2025, https://www.frontiersin.org/journals/cell-and-developmental-biology/articles/10.3389/fcell.2023.1278461/full
24. Cellular functions of cGAS-STING signaling - PubMed, accessed April 30, 2025, https://pubmed.ncbi.nlm.nih.gov/36437149/
25. Full article: Advances in understanding the role and mechanism of the cGAS-STING signaling pathway in ocular diseases - Taylor & Francis Online, accessed April 30, 2025, https://www.tandfonline.com/doi/full/10.1080/25785826.2025.2475626
26. Significance of the cGAS-STING Pathway in Health and Disease - PubMed, accessed April 30, 2025, https://pubmed.ncbi.nlm.nih.gov/37686127/
27. Development of human cGAS-specific small-molecule inhibitors for repression of dsDNA-triggered interferon expression, accessed April 30, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6529454/
28. Regulation and function of the cGAS-STING pathway: Mechanisms, post-tr | DDDT, accessed April 30, 2025, https://www.dovepress.com/regulation-and-function-of-the-cgas-sting-pathway-mechanisms-post-tran-peer-reviewed-fulltext-article-DDDT
29. Design, Synthesis, and Biochemical and Biological Evaluation of Novel 7-Deazapurine Cyclic Dinucleotide Analogues as STING Receptor Agonists, accessed April 30, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9620234/
30. Therapeutic Development by Targeting the cGAS-STING Pathway in Autoimmune Disease and Cancer - Frontiers, accessed April 30, 2025, https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2021.779425/full
31. WO2014099824A1 - Pharmaceutical targeting of a mammalian cyclic di-nucleotide signaling pathway - Google Patents, accessed April 30, 2025, https://patents.google.com/patent/WO2014099824A1/und
32. EP4267564A1 - Indole derivatives useful in treating conditions ..., accessed April 30, 2025, https://patents.google.com/patent/EP4267564A1/en
33. Targeting STING oligomerization with small-molecule inhibitors - PNAS, accessed April 30, 2025, https://www.pnas.org/doi/10.1073/pnas.2305420120
34. Discovery and optimization of narrow spectrum inhibitors of Tousled like kinase 2 (TLK2) using quantitative structure activity r - ePrints Soton - University of Southampton, accessed April 30, 2025, https://eprints.soton.ac.uk/491136/1/1-s2.0-

S022352342400237X-main.pdf
35. Potential Therapeutic Value of the STING Inhibitors - MDPI, accessed April 30, 2025, https://www.mdpi.com/1420-3049/28/7/3127
36. Regulation of the cGAS-STING Pathway - PubMed, accessed April 30, 2025, https://pubmed.ncbi.nlm.nih.gov/40085836/
37. Regulation and Function of the cGAS-STING Pathway: Mechanisms, Post-Translational Modifications, and Therapeutic Potential in Immunotherapy - PubMed, accessed April 30, 2025, https://pubmed.ncbi.nlm.nih.gov/40098909/?utm_source=FeedFetcher&utm_medium=rss&utm_campaign=None&utm_content=1-SjSZJSoHBGsnEXcLDjZZ8F-vz5YagNLIUYugSQFZXvZle9Rx&fc=None&ff=20250319003736&v=2.18.0.post9+e462414
38. Regulation and Function of the cGAS-STING Pathway: Mechanisms, Post-Translational Modifications, and Therapeutic Potential in Immunotherapy - PMC, accessed April 30, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11911240/
39. The Dual Role of cGAS-STING Signaling in COVID-19: Implications for Therapy - PMC, accessed April 30, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11899623/
40. The regulation of cGAS-STING signaling by RNA virus-derived components - PMC, accessed April 30, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11064393/
41. Discovery of Potent and Orally Bioavailable Pyrimidine Amide cGAS Inhibitors via Structure-Guided Hybridization | CoLab, accessed April 30, 2025, https://colab.ws/articles/10.1021/acsmedchemlett.4c00471
42. Editorial: Activation of the cGAS-STING pathway by extra-nuclear DNA and its pharmacognostic modulation in human disease - PMC, accessed April 30, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11813921/
43. WO2019201939A1 - Sting inhibitors - Google Patents, accessed April 30, 2025, https://patents.google.com/patent/WO2019201939A1/en
44. Orally Bioavailable and Site-Selective Covalent STING Inhibitor Derived from a Macrocyclic Marine Diterpenoid | Request PDF - ResearchGate, accessed April 30, 2025, https://www.researchgate.net/publication/389399869_Orally_Bioavailable_and_Site-Selective_Covalent_STING_Inhibitor_Derived_from_a_Macrocyclic_Marine_Diterpenoid
45. Orally bioavailable STING antagonist synthesized via multi-component Povarov–Doebner type reaction - RSC Publishing Home, accessed April 30, 2025, https://pubs.rsc.org/en/content/articlehtml/2024/cc/d4cc03228d
46. Small molecules targeting the innate immune cGAS–STING–TBK1 signaling pathway - PMC - PubMed Central, accessed April 30, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7745059/
47. (PDF) The role of cGAS-STING pathway ubiquitination in innate immunity and multiple diseases - ResearchGate, accessed April 30, 2025, https://www.researchgate.net/publication/389404128_The_role_of_cGAS-STING_pathway_ubiquitination_in_innate_immunity_and_multiple_diseases
48. IUPHAR ECR review: The cGAS-STING pathway: Novel functions beyond innate immune and emerging therapeutic opportunities - PubMed, accessed April 30, 2025, https://pubmed.ncbi.nlm.nih.gov/38216006/

49. The role of cGAS-STING pathway ubiquitination in innate immunity and multiple diseases - Frontiers, accessed April 30, 2025, https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1522200/full
50. Nanomedicines harnessing cGAS-STING pathway: sparking immune revitalization to transform 'cold' tumors into 'hot' tumors - PubMed Central, accessed April 30, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11664935/
51. Regulation of cGAS-STING signalling and its diversity of cellular ..., accessed April 30, 2025, https://pubmed.ncbi.nlm.nih.gov/39774812/
52. www.frontiersin.org, accessed April 30, 2025, https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1380517/full#:~:text=In%20fact%2C%20cGAS%20plays%20the,derived%20dendritic%20cells%20(DCs).
53. The role of cGAS-STING pathway ubiquitination in innate immunity and multiple diseases, accessed April 30, 2025, https://pubmed.ncbi.nlm.nih.gov/40028324/
54. Regulation and Function of the cGAS-STING Pathway: Mechanisms ..., accessed April 30, 2025, https://pubmed.ncbi.nlm.nih.gov/40098909/
55. Inhibitory targeting cGAS-STING-TBK1 axis: Emerging strategies for autoimmune diseases therapy - Frontiers, accessed April 30, 2025, https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2022.954129/full
56. Updated roles of cGAS-STING signaling in autoimmune diseases - PubMed, accessed April 30, 2025, https://pubmed.ncbi.nlm.nih.gov/37781360/
57. Medicinal chemistry perspective on cGAS-STING signaling pathway with small molecule inhibitors - ResearchGate, accessed April 30, 2025, https://www.researchgate.net/publication/363837827_Medicinal_chemistry_perspective_on_cGAS-STING_signaling_pathway_with_small_molecule_inhibitors
58. The role of the cGAS-STING pathway in chronic pulmonary inflammatory diseases - PubMed, accessed April 30, 2025, https://pubmed.ncbi.nlm.nih.gov/39540037/
59. The role of the cGAS-STING signaling pathway in viral infections, inflammatory and autoimmune diseases - PubMed, accessed April 30, 2025, https://pubmed.ncbi.nlm.nih.gov/38822084/
60. New Review Examines the cGAS–STING Pathway as a Therapeutic Target in Inflammatory Diseases, accessed April 30, 2025, https://www.ifmthera.com/news/new-review-examines-the-cgas-sting-pathway-as-a-therapeutic-target-in-inflammatory-diseases/
61. IFM Cinque, Inc. - Drug pipelines, Patents, Clinical trials - Patsnap Synapse, accessed April 30, 2025, https://synapse.patsnap.com/organization/6de11a66a5c302307b0bb4e78f96d8aa
62. Emerging role of the cGAS-STING signaling pathway in autoimmune diseases: Biologic function, mechanisms and clinical prospection - PubMed, accessed April 30, 2025, https://pubmed.ncbi.nlm.nih.gov/35902046/
63. The cGAS-STING pathway in cancer immunity: dual roles, therapeutic strategies, and clinical challenges - Portland Press, accessed April 30, 2025,

https://portlandpress.com/essaysbiochem/article/doi/10.1042/EBC20253006/235810/The-cGAS-STING-pathway-in-cancer-immunity-dual
64. Emerging Roles of cGAS-STING Signaling in Mediating Ocular Inflammation - PubMed, accessed April 30, 2025, https://pubmed.ncbi.nlm.nih.gov/37778330/
65. The cGAS–STING pathway as a therapeutic target in inflammatory diseases - PMC, accessed April 30, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8029610/
66. Targeting cGAS-STING: modulating the immune landscape of hepatic diseases - Frontiers, accessed April 30, 2025, https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1498323/full
67. Progress of cGAS-STING signaling pathway-based modulation of immune response by traditional Chinese medicine in clinical diseases - Frontiers, accessed April 30, 2025, https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1510628/full
68. ZNF593 regulates the cGAS-mediated innate immune response by attenuating cGAS-DNA binding - PubMed, accessed April 30, 2025, https://pubmed.ncbi.nlm.nih.gov/40210981/
69. A/Prof Seth Masters Qualification: PhD Institution: WEHI Date: 12/11/20 Title of Project: Blocking neuroinflammation to treat ALS Summary - Brain Foundation, accessed April 30, 2025, https://brainfoundation.org.au/wp-content/uploads/2019/10/Masters-Seth-Neuroinflammation-in-ALS-1.pdf
70. Ventus Therapeutics Announces Publication in Nature's Communications Chemistry Describing the Structure-based Optimization of a New Series of cGAS Inhibitors - BioSpace, accessed April 30, 2025, https://www.biospace.com/press-releases/ventus-therapeutics-announces-publication-in-natures-communications-chemistry-describing-the-structure-based-optimization-of-a-new-series-of-cgas-inhibitors
71. Structural insight into the cGAS active site explains differences between therapeutically relevant species - ResearchGate, accessed April 30, 2025, https://www.researchgate.net/publication/390095544_Structural_insight_into_the_cGAS_active_site_explains_differences_between_therapeutically_relevant_species
72. WO2020087126A1 - Methods of treatment, prevention and diagnosis - Google Patents, accessed April 30, 2025, https://patents.google.com/patent/WO2020087126A1/en
73. Identification and development of cGAS inhibitors and their uses to treat Alzheimer's disease, accessed April 30, 2025, https://pubmed.ncbi.nlm.nih.gov/39893084/
74. Discovery and characterization of a novel cGAS covalent inhibitor for ..., accessed April 30, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10043009/
75. PF-06928215 is a high affinity cGAS inhibitor. (A)... | Download Scientific Diagram - ResearchGate, accessed April 30, 2025, https://www.researchgate.net/figure/PF-06928215-is-a-high-affinity-cGAS-inhibitor-A-Concentration-dependent-inhibition-in_fig5_319974257
76. Discovery of PF-06928215 as a high affinity inhibitor of cGAS enabled by a novel fluorescence polarization assay | PLOS One, accessed April 30, 2025, https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0184843
77. Discovery of PF-06928215 as a high affinity inhibitor of cGAS enabled by a novel

fluorescence polarization assay - PubMed, accessed April 30, 2025, https://pubmed.ncbi.nlm.nih.gov/28934246/
78. PF-06928215 | cGAS Inhibitor - MedchemExpress.com, accessed April 30, 2025, https://www.medchemexpress.com/PF-06928215.html
79. PF-06928215 (CAS Number: 2378173-15-8) | Cayman Chemical, accessed April 30, 2025, https://www.caymanchem.com/product/32515/pf-06928215
80. IMSB-301 - Drug Targets, Indications, Patents - Patsnap Synapse, accessed April 30, 2025, https://synapse.patsnap.com/drug/ff8b7339f85a4b679ff485130d446f64
81. Press Release - ImmuneSensor Therapeutics, accessed April 30, 2025, https://www.immunesensor.com/news/091724/
82. ImmuneSensor Therapeutics Receives Orphan Drug and Rare Pediatric Disease Designations from the U.S. FDA for cGAS Inhibitor Drug Candidate, IMSB301, for the Treatment of Aicardi Goutières Syndrome (AGS) - GlobeNewswire, accessed April 30, 2025, https://www.globenewswire.com/news-release/2024/11/20/2984389/0/en/ImmuneSensor-Therapeutics-Receives-Orphan-Drug-and-Rare-Pediatric-Disease-Designations-from-the-U-S-FDA-for-cGAS-Inhibitor-Drug-Candidate-IMSB301-for-the-Treatment-of-Aicardi-Gouti.html
83. ImmuneSensor Therapeutics Initiates Dosing in Phase 1 Clinical Trial of Lead cGAS Inhibitor Drug Candidate, IMSB301 - BioSpace, accessed April 30, 2025, https://www.biospace.com/press-releases/immunesensor-therapeutics-initiates-dosing-in-phase-1-clinical-trial-of-lead-cgas-inhibitor-drug-candidate-imsb301
84. ImmuneSensor Therapeutics Starts Phase 1 Trial of Lead cGAS Inhibitor IMSB301, accessed April 30, 2025, https://synapse.patsnap.com/article/immunesensor-therapeutics-starts-phase-1-trial-of-lead-cgas-inhibitor-imsb301
85. ImmuneSensor Therapeutics Receives Clearance from Australian Regulators to Initiate a First-in-Human Phase 1 Clinical Trial of cGAS inhibitor Drug Candidate, IMSB301 - BioSpace, accessed April 30, 2025, https://www.biospace.com/immunesensor-therapeutics-receives-clearance-from-australian-regulators-to-initiate-a-first-in-human-phase-1-clinical-trial-of-cgas-inhibitor-drug-candidate-imsb301
86. ImmuneSensor Therapeutics Receives Clearance from Australian Regulators to Initiate a First-in-Human Phase 1 Clinical Trial of cGAS inhibitor Drug Candidate, IMSB301 - GlobeNewswire, accessed April 30, 2025, https://www.globenewswire.com/news-release/2024/08/19/2932072/0/en/ImmuneSensor-Therapeutics-Receives-Clearance-from-Australian-Regulators-to-Initiate-a-First-in-Human-Phase-1-Clinical-Trial-of-cGAS-inhibitor-Drug-Candidate-IMSB301.html
87. VENT-03 - Ventus Therapeutics, accessed April 30, 2025, https://www.ventustx.com/pipeline/cgas/
88. Ventus Therapeutics Announces Publication in Nature's Communications Chemistry Describing the Structure-based Optimization of a New Series of cGAS Inhibitors - Business Wire, accessed April 30, 2025, https://www.businesswire.com/news/home/20250324542820/en/Ventus-Therapeutics-Announces-Publication-in-Natures-Communications-Chemistry-Describing-the-Structure-based-Optimization-of-a-New-Series-of-cGAS-Inhibitors

89. Discovery of VENT-03: A Novel Clinical cGAS Inhibitor for the Treatment of SLE and Other Autoimmune Diseases - ACR Meeting Abstracts, accessed April 30, 2025, https://acrabstracts.org/abstract/discovery-of-vent-03-a-novel-clinical-cgas-inhibitor-for-the-treatment-of-sle-and-other-autoimmune-diseases/
90. Ventus Therapeutics Completes Phase 1 Trial of VENT-03, an Oral cGAS Inhibitor, accessed April 30, 2025, https://synapse.patsnap.com/article/ventus-therapeutics-completes-phase-1-trial-of-vent-03-an-oral-cgas-inhibitor
91. Press Release - ImmuneSensor Therapeutics, accessed April 30, 2025, https://www.immunesensor.com/news/100824/
92. Press Release - ImmuneSensor Therapeutics, accessed April 30, 2025, https://www.immunesensor.com/news/112024/
93. About Us - ImmuneSensor Therapeutics, accessed April 30, 2025, https://www.immunesensor.com/company/about/
94. ImmuneSensor Awarded $16 Million Grant from the Cancer Prevention and Research Institute of Texas (CPRIT) - BioSpace, accessed April 30, 2025, https://www.biospace.com/immunesensor-awarded-16-million-grant-from-the-cancer-prevention-and-research-institute-of-texas-cprit
95. ImmuneSensor Therapeutics Initiates Dosing in Phase 1 Clinical Trial of Lead cGAS Inhibitor Drug Candidate, IMSB301 - GlobeNewswire, accessed April 30, 2025, https://www.globenewswire.com/news-release/2024/10/08/2959610/0/en/ImmuneSensor-Therapeutics-Initiates-Dosing-in-Phase-1-Clinical-Trial-of-Lead-cGAS-Inhibitor-Drug-Candidate-IMSB301.html
96. Press Release - ImmuneSensor Therapeutics, accessed April 30, 2025, https://www.immunesensor.com/news/081924/
97. ImmuneSensor Therapeutics Initiates Phase 1 Trial of IMSB301, a Leading cGAS Inhibitor, accessed April 30, 2025, https://synapse.patsnap.com/blog/immunesensor-therapeutics-initiates-phase-1-trial-of-imsb301-a-leading-cgas-inhibitor
98. ImmuneSensor begins patient dosing in phase 1 trial of lead cGAS inhibitor drug candidate, IMSB301 to treat inflammatory and autoimmune diseases - Pharmabiz.com, accessed April 30, 2025, https://www.pharmabiz.com/NewsDetails.aspx?aid=172936&sid=2
99. Australian Authorities Approve ImmuneSensor Therapeutics' Phase 1 Trial for cGAS Inhibitor IMSB301 - Patsnap Synapse, accessed April 30, 2025, https://synapse.patsnap.com/blog/australian-authorities-approve-immunesensor-therapeutics-phase-1-trial-for-cgas-inhibitor-imsb301
100. ImmuneSensor Therapeutics Granted New U.S. Patent for its Oral cGAS Inhibitors, accessed April 30, 2025, https://www.globenewswire.com/news-release/2024/09/17/2947387/0/en/ImmuneSensor-Therapeutics-Granted-New-U-S-Patent-for-its-Oral-cGAS-Inhibitors.html
101. New Drug Designations - November 2024 - PharmaShots, accessed April 30, 2025, https://pharmashots.com/20501/new-drug-designations-november-2024
102. ImmuneSensor Therapeutics, Inc. - Drug pipelines, Patents, Clinical trials - Synapse, accessed April 30, 2025,

https://synapse.patsnap.com/organization/e02bd9c2e5bdddbf3b43c7cff78ac034
103. STING - Drugs, Indications, Patents - Patsnap Synapse, accessed April 30, 2025, https://synapse-patsnap-com.libproxy1.nus.edu.sg/target/3a796e4938384c68a5afc62701c5b97b
104. IMSB301 / ImmuneSensor Therap - LARVOL DELTA, accessed April 30, 2025, https://delta.larvol.com/Products/?ProductId=2c697175-01e1-4fea-9a8f-93f182cecc59
105. Press Releases - ImmuneSensor Therapeutics, accessed April 30, 2025, https://www.immunesensor.com/news/press-releases/
106. Clinical Trials - ImmuneSensor Therapeutics, accessed April 30, 2025, https://www.immunesensor.com/science/clinical-trials/
107. A Phase I randomized study of IMSB301 in healthy volunteers, accessed April 30, 2025, https://www.isrctn.com/pdf/90049550
108. A Phase I randomized study of IMSB301 in healthy volunteers - ISRCTN Registry, accessed April 30, 2025, https://www.isrctn.com/ISRCTN90049550
109. ImmuneSensor Therapeutics Initiates Phase 1 Trial of IMSB301, a Leading cGAS Inhibitor, accessed April 30, 2025, https://synapse-patsnap-com.libproxy1.nus.edu.sg/blog/immunesensor-therapeutics-initiates-phase-1-trial-of-imsb301-a-leading-cgas-inhibitor
110. Ventus Therapeutics - Products, Competitors, Financials, Employees, Headquarters Locations - CB Insights, accessed April 30, 2025, https://www.cbinsights.com/company/ventus-therapeutics
111. Marcelo Bigal, MD, PhD: VENT-03's Modality Offers Hope for Targeted Therapy in Skin Disorders - Dermatology Times, accessed April 30, 2025, https://www.dermatologytimes.com/view/marcelo-bigal-md-phd-vent-03-s-modality-offers-hope-for-targeted-therapy-in-skin-disorders
112. Ventus Therapeutics Announces Successful Completion of Phase 1 Clinical Trial of VENT-03, a First-in-Class, Orally Administered cGAS Inhibitor, accessed April 30, 2025, https://www.ventustx.com/ventus-therapeutics-announces-successful-completion-of-phase-1-clinical-trial-of-vent-03-a-first-in-class-orally-administered-cgas-inhibitor/
113. Ventus Therapeutics Announces Successful Completion of Phase 1 Clinical Trial of VENT-03, a First-in-Class, Orally Administered cGAS Inhibitor | Financial Post, accessed April 30, 2025, https://financialpost.com/pmn/business-wire-news-releases-pmn/ventus-therapeutics-announces-successful-completion-of-phase-1-clinical-trial-of-vent-03-a-first-in-class-orally-administered-cgas-inhibitor
114. Patients - Ventus Therapeutics, accessed April 30, 2025, https://www.ventustx.com/patients/
115. Ventus Therapeutics Initiates Clinical Testing of VENT-03, a First-in-Class, Orally Administered cGAS Inhibitor, accessed April 30, 2025, https://www.ventustx.com/ventus-therapeutics-initiates-clinical-testing-of-vent-03-a-first-in-class-orally-administered-cgas-inhibitor/
116. Ventus gears up for phase 2 study of potential daily oral lupus drug after passing early-stage test - Fierce Biotech, accessed April 30, 2025, https://www.fiercebiotech.com/biotech/ventus-gears-phase-2-study-potential-daily-oral-

lupus-drug-after-passing-early-stage
117. UPDATE: Ventus Therapeutics Announces Positive Phase 1 Trial Results for Investigational Drug, VENT-03, for Lupus, accessed April 30, 2025, https://www.lupus.org/news/update-ventus-therapeutics-announces-positive-phase-1-trial-results-for-investigational-drug
118. Ventus Therapeutics Announces Publication in Nature's Communications Chemistry Describing the Structure-based Optimization of a New Series ofcGAS Inhibitors, accessed April 30, 2025, https://www.ventustx.com/ventus-therapeutics-announces-publication-in-natures-communications-chemistry-describing-the-structure-based-optimization-of-a-new-series-ofcgas-inhibitors/
119. Latest News - Ventus Therapeutics, accessed April 30, 2025, https://www.ventustx.com/news/latest-news/
120. Ventus Therapeutics Closes $140 Million Series C Financing, accessed April 30, 2025, https://www.ventustx.com/ventus-therapeutics-closes-140-million-series-c-financing/
121. Ventus doses first participant in Phase I clinical trial of VENT-03, accessed April 30, 2025, https://www.clinicaltrialsarena.com/news/ventus-trial-vent-03/
122. Ventus Therapeutics Announces Successful Completion of Phase 1 Clinical Trial of VENT-03, a First-in-Class, Orally Administered cGAS Inhibitor - Business Wire, accessed April 30, 2025, https://www.businesswire.com/news/home/20241030939211/en/Ventus-Therapeutics-Announces-Successful-Completion-of-Phase-1-Clinical-Trial-of-VENT-03-a-First-in-Class-Orally-Administered-cGAS-Inhibitor
123. Ventus Therapeutics Announces Results from Phase 1 Clinical Trial of VENT-02, a Novel, Orally Administered, Brain-Penetrant NLRP3 Inhibitor | Financial Post, accessed April 30, 2025, https://financialpost.com/pmn/business-wire-news-releases-pmn/ventus-therapeutics-announces-results-from-phase-1-clinical-trial-of-vent-02-a-novel-orally-administered-brain-penetrant-nlrp3-inhibitor
124. Ventus Therapeutics' partner Novo Nordisk doses first participant in phase 1 clinical study for NNC6022-0001, an oral NLRP3 inhibitor - Pharmabiz.com, accessed April 30, 2025, https://www.pharmabiz.com/NewsDetails.aspx?aid=168958&sid=2
125. Ventus Therapeutics, Inc. - Drug pipelines, Patents, Clinical trials - Patsnap Synapse, accessed April 30, 2025, https://synapse-patsnap-com.libproxy1.nus.edu.sg/organization/3c5d873a30f5ea7c8e0c6e9ca0820d52
126. VENT-03 - Drug Targets, Indications, Patents - Patsnap Synapse, accessed April 30, 2025, https://synapse.patsnap.com/drug/98392000f7404814935800b1d04f7a3e
127. Ventus Therapeutics to Present at 2025 Bloom Burton & Co. Healthcare Investor Conference, accessed April 30, 2025, https://www.biospace.com/press-releases/ventus-therapeutics-to-present-at-2025-bloom-burton-co-healthcare-investor-conference
128. Ventus Therapeutics Announces First Participant Dosed in Clinical Study with an NLRP3 Inhibitor Licensed Exclusively to Novo Nordisk, accessed April 30, 2025, https://www.ventustx.com/ventus-therapeutics-announces-first-participant-dosed-in-clinical-study-with-an-nlrp3-inhibitor-licensed-exclusively-to-novo-nordisk/
129. Ventus Therapeutics Inc., Montréal - [LSUS] Life-Sciences-USA.com, accessed April 30, 2025, https://www.life-sciences-usa.com/organisation/ventus-therapeutics-inc-montr-

bec-canada-north-america-2001-49322.html
130. Ventus Therapeutics Announces Nature Reviews Immunology Publication Demonstrating the Promise of Caspase-4/5 as Therapeutic Targets - FirstWord Pharma, accessed April 30, 2025, https://firstwordpharma.com/story/5940383
131. Ventus Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial Evaluating VENT-02, an Oral, Brain-Penetrant NLRP3 Inhibitor, in Parkinson's Disease - BioSpace, accessed April 30, 2025, https://www.biospace.com/press-releases/ventus-therapeutics-announces-first-patient-dosed-in-phase-2a-clinical-trial-evaluating-vent-02-an-oral-brain-penetrant-nlrp3-inhibitor-in-parkinsons-disease
132. Ventus Therapeutics: The Power of Resolution, accessed April 30, 2025, https://www.ventustx.com/
133. Pfizer ends early-stage trial as STING programmes evolve - FirstWord Pharma, accessed April 30, 2025, https://firstwordpharma.com/story/5942307
134. Official Protocol Title: NCT number: Document Date: - ClinicalTrials.gov, accessed April 30, 2025, https://cdn.clinicaltrials.gov/large-docs/76/NCT03010176/Prot_SAP_000.pdf
135. Clinical applications of STING agonists in cancer immunotherapy: current progress and future prospects - Frontiers, accessed April 30, 2025, https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1485546/full
136. Targeting Stimulator of Interferon Genes (STING): A Medicinal Chemistry Perspective | Request PDF - ResearchGate, accessed April 30, 2025, https://www.researchgate.net/publication/337882378_Targeting_Stimulator_of_Interferon_Genes_STING_A_Medicinal_Chemistry_Perspective
137. Safety and Efficacy Study of IMSA101 in Refractory Malignancies - Cancer Trial Results, accessed April 30, 2025, https://clin.larvol.com/trial-detail/NCT04020185
138. All individual trials at ImmuneSensor Therapeutics Inc. - FDAAA Trials Tracker, accessed April 30, 2025, https://fdaaa.trialstracker.net/sponsor/immunesensor-therapeutics-inc/
139. Two phase 2A clinical trials to evaluate the safety and efficacy of IMSA101 in, accessed April 30, 2025, https://ascopubs.org/doi/pdf/10.1200/JCO.2024.42.16_suppl.TPS2685
140. Press Release - ImmuneSensor Therapeutics, accessed April 30, 2025, https://www.immunesensor.com/news/050124/
141. Novartis Acquires IFM Due to Develop First-In-Class STING Antagonist Program Targeting Innate Immune System | IFM Therapeutics (en-US), accessed April 30, 2025, https://www.ifmthera.com/news/novartis-acquires-ifm-due-to-develop-first-in-class-sting-antagonist-program-targeting-innate-immune-system/
142. Novartis buys IFM subsidiary for $90M+; set to develop STING antagonist program that targets immune system | ROI-NJ, accessed April 30, 2025, https://www.roi-nj.com/2024/03/13/healthcare/novartis-buys-ifm-subsidiary-for-90m-set-to-develop-sting-antagonist-program-that-targets-immune-system/
143. Novartis Acquires IFM Due to Develop First-In-Class STING Antagonist Program Targeting Innate Immune System - PR Newswire, accessed April 30, 2025, https://www.prnewswire.com/news-releases/novartis-acquires-ifm-due-to-develop-first-in-class-sting-antagonist-program-targeting-innate-immune-system-302087547.html

144. Novartis exercises option to acquire IFM Due for $835m - Pharmaceutical Technology, accessed April 30, 2025, https://www.pharmaceutical-technology.com/news/novartis-ifm-due/
145. Novartis Buys IFM Due in Potential $835M Deal, Gains Access to Antagonist Program, accessed April 30, 2025, https://www.biospace.com/novartis-buys-ifm-due-in-potential-835m-deal-gains-access-to-antagonist-program
146. Novartis hits the cGAS, taking option to buy IFM unit for $90M upfront - Fierce Biotech, accessed April 30, 2025, https://www.fiercebiotech.com/biotech/novartis-hits-cgas-taking-option-buy-ifm-unit-90m-upfront
147. Discovery of MK-1454: A Potent Cyclic Dinucleotide Stimulator of Interferon Genes Agonist for the Treatment of Cancer | Journal of Medicinal Chemistry - ACS Publications, accessed April 30, 2025, https://pubs.acs.org/doi/abs/10.1021/acs.jmedchem.1c02197
148. Discovery of Small Molecule Cyclic GMP-AMP Synthase Inhibitors - ResearchGate, accessed April 30, 2025, https://www.researchgate.net/publication/337925116_Discovery_of_Small_Molecule_Cyclic_GMP-AMP_Synthase_Inhibitors
149. Discovery of Potent and Orally Bioavailable Pyrimidine Amide cGAS Inhibitors via Structure-Guided Hybridization - PubMed, accessed April 30, 2025, https://pubmed.ncbi.nlm.nih.gov/39691514
150. Discovery of novel cGAS inhibitors based on natural flavonoids - PubMed, accessed April 30, 2025, https://pubmed.ncbi.nlm.nih.gov/37666112/
151. Manipulating the cGAS-STING Axis: advancing innovative strategies for osteosarcoma therapeutics - PMC - PubMed Central, accessed April 30, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11842356/
152. A small-molecule inhibitor and degrader of the RNF5 ubiquitin ligase, accessed April 30, 2025, https://www.molbiolcell.org/doi/10.1091/mbc.E22-06-0233
153. The Cytosolic DNA-Sensing cGAS–STING Pathway in Cancer - AACR Journals, accessed April 30, 2025, https://aacrjournals.org/cancerdiscovery/article/10/1/26/2314/The-Cytosolic-DNA-Sensing-cGAS-STING-Pathway-in
154. cGAS/STING pathway and gastrointestinal cancer: Mechanisms and diagnostic and therapeutic targets (Review) - Spandidos Publications, accessed April 30, 2025, https://www.spandidos-publications.com/10.3892/or.2024.8848?text=fulltext
155. Emerging mechanisms and implications of cGAS-STING signaling in cancer immunotherapy strategies, accessed April 30, 2025, https://www.cancerbiomed.org/content/early/2024/01/03/j.issn.2095-3941.2023.0440
156. Biological and therapeutic significance of targeting NLRP3 inflammasome in the brain and the current efforts to develop brain-penetrant inhibitors - PMC - PubMed Central, accessed April 30, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11955958/
157. ImmuneSensor Therapeutics | IMSA101 | cGAS-STING pathway, accessed April 30, 2025, https://www.immunesensor.com/
158. ImmuneSensor Therapeutics 2025 Company Profile: Valuation, Funding & Investors, accessed April 30, 2025, https://pitchbook.com/profiles/company/343149-58
159. Ventus Therapeutics Launches with $60 Million Series A, accessed April 30, 2025,

https://www.ventustx.com/ventus-therapeutics-launches-with-60-million-series-a-2/
160. Ventus Therapeutics Announces Results from Phase 1 Clinical Trial of VENT-02, a Novel, Orally Administered, Brain-Penetrant NLRP3 Inhibitor, accessed April 30, 2025, https://www.ventustx.com/ventus-therapeutics-announces-results-from-phase-1-clinical-trial-of-vent-02-a-novel-orally-administered-brain-penetrant-nlrp3-inhibitor/
161. Ventus Therapeutics Initiates Dosing in a Phase 1 Clinical Trial of VENT-02, a Novel, Orally Administered, Brain-Penetrant NLRP3 Inhibitor, accessed April 30, 2025, https://www.ventustx.com/ventus-therapeutics-initiates-dosing-in-a-phase-1-clinical-trial-of-vent-02-a-novel-orally-administered-brain-penetrant-nlrp3-inhibitor/
162. Recent advances in the development of STING inhibitors: an updated patent review - informa Healthcare, accessed April 30, 2025, https://www.informahealthcare.com/doi/epub/10.1080/13543776.2022.2144220
163. IFM Therapeutics Announces Extension of Collaboration Agreement for cGAS-STING Subsidiary, IFM Due, accessed April 30, 2025, https://www.ifmthera.com/news/ifm-therapeutics-announces-extension-of-collaboration-agreement-for-cgas-sting-subsidiary-ifm-due/
164. Veralox Therapeutics Expands Its Pipeline with the Exclusive Option to Acquire Nudge Therapeutics, accessed April 30, 2025, https://veralox.com/news/veralox-therapeutics-expands-its-pipeline-with-the-exclusive-option-to-acquire-nudge-therapeutics/
165. Veralox Therapeutics Acquires Nudge Therapeutics to Advance Preclinical cGAS Inhibitor Compounds - BioPharma BoardRoom, accessed April 30, 2025, https://biopharmaboardroom.com/news/73/2753/veralox-therapeutics-acquires-nudge-therapeutics-to-advance-preclinical-cgas-inhibitor-compounds.html
166. Veralox Therapeutics Expands Its Pipeline with the Exclusive Option to Acquire Nudge Therapeutics - PR Newswire, accessed April 30, 2025, https://www.prnewswire.com/news-releases/veralox-therapeutics-expands-its-pipeline-with-the-exclusive-option-to-acquire-nudge-therapeutics-302347548.html
167. Company News - Page 3 of 3 - Veralox Therapeutics, accessed April 30, 2025, https://veralox.com/news/page/3/
168. Veralox Therapeutics to Acquire Nudge Therapeutics, Expanding its Portfolio - PharmaShots, accessed April 30, 2025, https://pharmashots.com/20619/veralox-therapeutics-to-acquire-nudge-therapeutics-expanding-its-portfolio
169. Company News - Veralox Therapeutics, accessed April 30, 2025, https://veralox.com/news/
170. WO2020142735A1 - Inhibitors of cgas activity as therapeutic agents - Google Patents, accessed April 30, 2025, https://patents.google.com/patent/WO2020142735A1/en
171. WO2017176812A1 - cGAS ANTAGONIST COMPOUNDS - Google ..., accessed April 30, 2025, https://patents.google.com/patent/WO2017176812A1/en
172. Intervention of cGAS–STING signaling in sterile inflammatory diseases - PMC, accessed April 30, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9122663/
173. Orally Bioavailable and Site-Selective Covalent STING Inhibitor Derived from a Macrocyclic Marine Diterpenoid | Journal of Medicinal Chemistry - ACS Publications, accessed April 30, 2025, https://pubs.acs.org/doi/10.1021/acs.jmedchem.4c02665

174. Structure–Activity Relationship Study of 1H-Pyrrole-3-carbonitrile Derivatives as STING Receptor Agonists - PMC, accessed April 30, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10424313/
175. A kinase-cGAS cascade to synthesize a therapeutic STING activator - ResearchGate, accessed April 30, 2025, https://www.researchgate.net/publication/359270808_A_kinase-cGAS_cascade_to_synthesize_a_therapeutic_STING_activator
176. Michael D. Altman's research works | Merck & Co. and other places - ResearchGate, accessed April 30, 2025, https://www.researchgate.net/scientific-contributions/Michael-D-Altman-56114381
177. US10633411B2 - Pharmaceutical targeting of a mammalian cyclic di-nucleotide signaling pathway - Google Patents, accessed April 30, 2025, https://patents.google.com/patent/US10633411B2/en
178. US10336786B2 - Pharmaceutical targeting of a mammalian cyclic di-nucleotide signaling pathway - Google Patents, accessed April 30, 2025, https://patents.google.com/patent/US10336786B2/und
179. Design, Synthesis, and Biological Evaluation of Selective STING Synergists That Enhance cGAMP-STING Pathway Activation without Inherent Agonist Activity | Journal of Medicinal Chemistry - ACS Publications, accessed April 30, 2025, https://pubs.acs.org/doi/10.1021/acs.jmedchem.4c03131
180. Target-Based Evaluation of “Drug-Like” Properties and Ligand Efficiencies | Journal of Medicinal Chemistry - ACS Publications, accessed April 30, 2025, https://pubs.acs.org/doi/abs/10.1021/acs.jmedchem.1c00416
181. Targeting the NLRP3 Inflammasome: Novel Inhibitors for Cardiovascular Disease Management - Preprints.org, accessed April 30, 2025, https://www.preprints.org/manuscript/202501.1297/v1/download
182. Top 1277 Journal of Medicinal Chemistry papers published in 2024 - SciSpace, accessed April 30, 2025, https://scispace.com/journals/journal-of-medicinal-chemistry-1vm1ozsh/2024
183. News | IFM Therapeutics, accessed April 30, 2025, https://www.ifmthera.com/news
184. News & Events - IFM Therapeutics, accessed April 30, 2025, https://www.ifmthera.com/news-events/
185. Novo Nordisk Sinks $70M Cash into Ventus' NLRP3 Inhibitor - BioSpace, accessed April 30, 2025, https://www.biospace.com/ventus-licenses-nlrp3-asset-to-novo-nordisk-in-700-million-deal
186. EY Predicts Smarter, Smaller M&A in Biotech and Pharma for 2025 - GeneOnline News, accessed April 30, 2025, https://www.geneonline.com/ey-predicts-smarter-smaller-ma-in-biotech-and-pharma-for-2025/
187. Biotech and Pharma M&A: 2025 Outlook - AlphaSense, accessed April 30, 2025, https://www.alpha-sense.com/blog/trends/biotech-pharma-m-and-a-2025-outlook/
188. Life Sciences Under the Microscope: Key 2024 Takeaways and What's Ahead for 2025, accessed April 30, 2025, https://www.ropesgray.com/en/insights/alerts/2025/02/key-takeaways-from-the-life-sciences-industry-in-2024-and-whats-next

189. Top biotech deals of February 2025 - Labiotech.eu, accessed April 30, 2025, https://www.labiotech.eu/trends-news/top-biotech-deals-of-february-2025/
190. Aicardi Goutieres Syndrome Market Report - DelveInsight, accessed April 30, 2025, https://www.delveinsight.com/report-store/aicardi-goutieres-syndrome-market
191. ImmuneSensor Therapeutics Receives Orphan Drug and Rare Pediatric Disease Designations from the U.S. FDA for cGAS Inhibitor Drug Candidate, IMSB301, for the Treatment of Aicardi Goutières Syndrome (AGS) - BioSpace, accessed April 30, 2025, https://www.biospace.com/press-releases/immunesensor-therapeutics-receives-orphan-drug-and-rare-pediatric-disease-designations-from-the-u-s-fda-for-cgas-inhibitor-drug-candidate-imsb301-for-the-treatment-of-aicardi-goutieres-syndrome-ags
192. 10-K - SEC.gov, accessed April 30, 2025, https://www.sec.gov/Archives/edgar/data/1851194/000095017025029245/vtyx-20241231.htm
193. 10-K - SEC.gov, accessed April 30, 2025, https://www.sec.gov/Archives/edgar/data/1851194/000095017023009501/vtyx-20221231.htm
194. 2024 Annual Report Annual Report - Acquire Media, accessed April 30, 2025, http://archive.fast-edgar.com/20250421/AIBYEG2C8W229ZZU222W2ZZZW698Z2V2Z272/tm257809d2_ars.pdf
195. Sitocabnagene loxiveluecel - Drug Targets, Indications, Patents - Patsnap Synapse, accessed April 30, 2025, https://synapse.patsnap.com/drug/5b476b9e97954acca1eabf758dacb827
196. KP-104 - Drug Targets, Indications, Patents - Patsnap Synapse, accessed April 30, 2025, https://synapse.patsnap.com/drug/bf6f738dbc654a85ada83df0a8ce7b78
197. Veralox Therapeutics Expands Its Pipeline with the Exclusive Option to Acquire Nudge ... - BioSpace, accessed April 30, 2025, https://www.biospace.com/press-releases/veralox-therapeutics-expands-its-pipeline-with-the-exclusive-option-to-acquire-nudge-therapeutics
198. Sanofi's rilzabrutinib gains FDA orphan drug status - Pharmaceutical Technology, accessed April 30, 2025, https://www.pharmaceutical-technology.com/news/sanofis-rilzabrutinib-fda/
199. Ventus to Advance cGAS Inhibitor as New Treatment for Lupus, accessed April 30, 2025, https://lupusnewstoday.com/news/ventus-advance-cgas-inhibitor-new-treatment-investigational/
200. accessed December 31, 1969, https://pubmed.ncbi.nlm.nih.gov/39691514/
201. Design, Synthesis, and Biological Evaluation of Selective STING Synergists That Enhance cGAMP-STING Pathway Activation without Inherent Agonist Activity - PubMed, accessed April 30, 2025, https://pubmed.ncbi.nlm.nih.gov/40298091/